
Title:
Ketamine
Text:
Dissociative medication
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}For the functional group referred to as ketimine, see Imine.


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}KetamineClinical dataTrade namesKetalar, othersOther namesCI-581; CL-369; CM-52372-2[1]AHFS/Drugs.comMonographLicense data
US DailyMed: Ketamine
US FDA: Ketamine
Pregnancycategory
AU: B3[2]

AddictionliabilityLow–moderate[3]                                                      Routes ofadministrationAny[4][5][6][7]Drug classNMDA receptor antagonists; General anesthetics; Dissociative hallucinogens; Analgesics; AntidepressantsATC codeN01AX03 (WHO) Legal statusLegal status
AU: S8 (Controlled drug) 
CA: Schedule I 
UK: Class B 
US: Schedule III 
UN: Unscheduled 
In general: ℞ (Prescription only)
Pharmacokinetic dataBioavailability
Intravenous: 100%[6]
Intramuscular: 93%[6]
Subcutaneous: high[8]
Epidural: 77%[9]
Intranasal: 45–50%[6][10]
Sublingual: 24–30%[6][11]
Rectal: 25–30%[10]
By mouth: 16–20%[6][10]
Protein binding23 to 47%.[12]MetabolismLiver, intestine (oral):[6][16][17]
Major: CYP3A4, CYP2B6
Metabolites
Norketamine
Dehydronorketamine
Hydroxynorketamine
Onset of action
Intravenous: seconds[13]
Intramuscular: 1–5 min[13][14]
Subcutaneous: 15–30 min[14]
Insufflation: 5–10 min[13]
By mouth: 15–30 min[13][14]
Elimination half-life
Ketamine: 2.5–3 hours[13][6]
Norketamine: 12 hours[14]
Duration of action
Intramuscular: 0.5–2 hours[14]
Insufflation: 45–60 min[13]
By mouth: 1–6+ hours[13][14]
Excretion
Urine: 91%[15]
Feces: 3%[15]
Identifiersshow
IUPAC name
(RS)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
CAS Number6740-88-1 Y 
33643-46-8 (esketamine)
33643-49-1 (arketamine)
as HCl: 1867-66-9 YPubChem CID3821IUPHAR/BPS4233DrugBankDB01221 YChemSpider3689 YUNII690G0D6V8HKEGGD08098 Yas HCl: D00711 YChEBICHEBI:6121 YChEMBLChEMBL742 YCompTox Dashboard (EPA)DTXSID8023187 ECHA InfoCard100.027.095 Chemical and physical dataFormulaC13H16ClNOMolar mass237.73 g·mol−13D model (JSmol)Interactive imageChiralityRacemic mixture:[13]
Esketamine (S(+)-isomer)
Arketamine (R(−)-isomer)
Melting point92[18] °C (198 °F)show
SMILES
Clc1ccccc1C2(NC)CCCCC2=O
show
InChI
InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3 YKey:YQEZLKZALYSWHR-UHFFFAOYSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Ketamine is a medication primarily used for induction and maintenance of anesthesia. It induces dissociative anesthesia, a trance-like state providing pain relief, sedation, and amnesia.[19] The distinguishing features of ketamine anesthesia are preserved breathing and airway reflexes, stimulated heart function with increased blood pressure, and moderate bronchodilation.[19] At lower, sub-anesthetic doses, ketamine is a promising agent for pain and treatment-resistant depression.[20] However, the antidepressant action of a single administration of ketamine wanes with time, and the effects of repeated use have not been sufficiently studied.[21][22][23]
Psychiatric side effects are frequent as well as raised blood pressure and nausea. Liver and urinary toxicity are common among regular users of high doses of ketamine for recreational purposes. Ketamine is an NMDA receptor antagonist, and that accounts for most of its actions except the antidepressive effect, the mechanism of which is a matter of much research and debate.
Ketamine was first synthesized in 1962 and approved for use in the United States in 1970. It was regularly used on dogs and horses and extensively used for surgical anaesthesia in the Vietnam War.[24] Ketamine is also used as a recreational drug, both in powder and liquid form, often referred to as "Special K" for its hallucinogenic and dissociative effects.[25]
It is on the World Health Organization's List of Essential Medicines.[26] It is available as a generic medication.[27]

.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}Contents

1 Medical uses

1.1 Anesthesia
1.2 Pain
1.3 Depression

1.3.1 Near-death experience


1.4 Seizures


2 Contraindications
3 Side effects

3.1 Urinary and liver toxicity
3.2 Dependence and tolerance


4 Interactions
5 Pharmacology

5.1 Pharmacodynamics

5.1.1 Mechanism of action
5.1.2 Molecular targets
5.1.3 Relationships between levels and effects


5.2 Pharmacokinetics


6 Chemistry

6.1 Synthesis
6.2 Structure
6.3 Detection


7 History
8 Society and culture

8.1 Legal status
8.2 Recreational use


9 Veterinary medicine
10 References
11 External links



Medical uses[edit]
Anesthesia[edit]
The use of ketamine in anesthesia reflects its characteristics. It is a drug of choice for short-term  procedures when muscle relaxation is not required.[28] The effect of ketamine on the respiratory and circulatory systems is different from that of other anesthetics. It suppresses breathing much less than most other available anesthetics.[29] When used at anesthetic doses, ketamine usually stimulates rather than depresses the circulatory system.[30] Protective airway reflexes are preserved,[31] and it is sometimes possible to administer ketamine anesthesia without protective measures to the airways.[28] Psychotomimetic effects limit the acceptance of ketamine; however, they can be counteracted by administering benzodiazepines or propofol.[32]
Ketamine is frequently used in severely injured people and appears to be safe in this group.[33] It has been widely used for emergency surgery in field conditions in war zones,[34] for example, during the Vietnam War.[35] A 2011 clinical practice guideline supports the use of ketamine as a sedative in emergency medicine, including during physically painful procedures.[19] It is the drug of choice for people in traumatic shock who are at risk of hypotension.[36] Low blood pressure is harmful in people with severe head injury,[37] and ketamine is least likely to cause low blood pressure and often even able to prevent it.[38][39]
Ketamine is an option in children, as the sole anesthetic for minor procedures or as an induction agent followed by neuromuscular blocker and tracheal intubation[34] In particular, children with cyanotic heart disease and neuromuscular disorders are good candidates for ketamine anesthesia.[32]
Due to the bronchodilating properties of ketamine, it can be used for anesthesia in people with asthma, chronic obstructive airway disease, and with severe reactive airway disease including active bronchospasm.[34][32][40]

Pain[edit]
Ketamine infusions are used for acute pain treatment in emergency departments and in the perioperative period in individuals with refractory pain. The doses are lower than those used for anesthesia; they are usually referred to as sub-anesthetic doses. Adjunctive to morphine or on its own, ketamine reduces morphine use, pain level, nausea, and vomiting after surgery. Ketamine is likely to be most beneficial for surgical patients when severe post-operative pain is expected and for opioid-tolerant patients.[41][42]
Ketamine is especially useful in the prehospital setting, due to its effectiveness and low risk of respiratory depression.[43]
Ketamine has similar efficacy to opioids in a hospital emergency department setting for management of acute pain and for control of procedural pain.[44] It may also prevent opioid-induced hyperalgesia[45][46] and postanesthetic shivering.[47]
For chronic pain, ketamine is used as an intravenous analgesic, particularly, if the pain is neuropathic.[48] It has the added benefit of counteracting spinal sensitization or wind-up phenomena experienced with chronic pain.[49] In multiple clinical trials, ketamine infusions delivered short-term pain relief in neuropathic pain diagnoses, pain after traumatic spine injury, fibromyalgia, and complex regional pain syndrome (CRPS).[48] However, the 2018 consensus guidelines on chronic pain concluded that, overall, there is only weak evidence in favor of ketamine use in spinal injury pain, moderate evidence in favor of ketamine for CRPS, and weak or no evidence for ketamine in mixed neuropathic pain, fibromyalgia, and cancer pain. In particular, only for CRPS there is evidence of medium to longer term pain relief.[48]

Depression[edit]
See also: Esketamine § Depression
Ketamine is a robust and rapid-acting antidepressant, albeit its effect is transient.[50] Intravenous ketamine infusion in treatment resistant depression results in improved mood within 4 hours reaching the peak at 24 hours.[20][21] A single dose of intravenous ketamine results in a response rate over 60% as early as 4.5 hours after the dose (with a sustained effect after 24 hours) and over 40% after 7 days.[51] Although there are only a few pilot studies studying the optimal dose, increasing evidence suggests that 0.5 mg/kg dose injected over 40 minutes gives an optimal outcome.[52] The antidepressant effect of ketamine is diminished at 7 days, and most patients relapse within 10 days, although for a significant minority the improvement may last 30 days and longer.[21][22][51][53] The main challenge with ketamine treatment is what to do when the antidepressant effect expires. The maintenance therapy with ketamine (from twice a week to once in two weeks) appears to be a promising option, although the evidence to firmly recommend it is insufficient.[21][22][23] Ketamine may also decrease suicidal thoughts for up to three days after the injection.[54]
Ketamine has not been approved for use as an antidepressant, but the Canadian Network for Mood and
Anxiety Treatments (CANMAT) recommends it as a third-line treatment for depression.[22] One of the enantiomers of ketamine, esketamine, has been approved as a nasal spray for treatment-resistant depression in the United States and elsewhere (see Esketamine § Depression). A comparative meta-analysis of clinical trials suggests superior efficacy of intravenous ketamine over intranasal esketamine, with intravenous ketamine having greater overall response and remission rates and a lower number of dropouts.[55] Ketamine may also be effective for bipolar depression, but the data on its use for this form of depression is scarce.[56]

Near-death experience[edit]
Most people who were able to remember their dreams during ketamine anesthesia report near-death experiences (NDE) when the widest possible definition of a NDE is used.[57] Ketamine can reproduce features which have commonly been associated with NDE's.[58] A 2019 large-scale study found that most drug-induced NDEs were linked to ketamine.[59]

Seizures[edit]
Ketamine is sometimes used in the treatment of status epilepticus that has failed to adequately respond to standard treatments, although only limited evidence (case studies and no randomized controlled trials) exists in its favor.[60][61]

Contraindications[edit]
Main contraindications for ketamine:[48][41]

Severe cardiovascular disease such as unstable angina or poorly controlled hypertension
Increased intracranial or intraocular pressure. Both of these contraindications are controversial [41]
Poorly controlled psychosis
Severe liver disease such as cirrhosis
Pregnancy
Active substance use disorder (for serial ketamine injections)
Age less than 3 months [10]
Side effects[edit]
At anesthetic doses, 10–20% of adults (1–2% of children)[10] experience adverse psychiatric reactions that occur during emergence from anesthesia, ranging from dreams and dysphoria to hallucinations and emergence delirium.[62] These can be counteracted by pretreating with a benzodiazepine or propofol.[62][32] Ketamine anesthesia commonly causes tonic-clonic movements (greater than 10% of people) and rarely hypertonia.[14][62] Vomiting can be expected in 5–15% of the patients; pre-treatment with propofol mitigates it as well.[10][62] Laryngospasm occurs only rarely with ketamine. Ketamine, generally, stimulates breathing; however, in the first 2–3 minutes of a high-dose rapid intravenous injection it may cause a transient respiratory depression.[62]
At lower sub-anesthetic doses, psychiatric side effects are prominent. A majority of patients feel strange, spacey, woozy or floating, or have visual distortions or numbness. Also very frequent (20–50%) are difficulty speaking, confusion, euphoria, drowsiness, and difficulty concentrating. The symptoms of psychosis such as going into a hole, disappearing, feeling melting, experiencing colors and hallucinations are described by 6–10% of people. Dizziness, blurred vision, dry mouth, hypertension, nausea, increased/decreased body temperature, or feeling flushed are the common (>10%) non-psychiatric side effects. All these adverse effects are most pronounced by the end of the injection, dramatically reduced 40 min after, and completely disappear within 4 hours after the injection.[63]

Urinary and liver toxicity[edit]
Urinary toxicity occurs primarily in people who use large amounts of ketamine routinely, with 20–30% of frequent users having bladder complaints.[48][64] It includes a range of disorders from cystitis to hydronephrosis to kidney failure.[65] The typical symptoms of ketamine-induced cystitis are frequent urination, dysuria, and urinary urgency sometimes accompanied by pain during urination and blood in urine.[66]  The damage to the bladder wall has similarities to both interstitial and eosinophilic cystitis. The wall is thickened, and the functional bladder capacity is as low as 10–150 mL.[65]
Management of ketamine-induced cystitis involves ketamine cessation as the first step. This is followed by NSAIDs and anticholinergics and, if the response is insufficient, by tramadol. The second line treatments are epithelium-protective agents such as oral pentosan polysulfate or intravesical (intra-bladder) instillation of hyaluronic acid. Intravesical botulinum toxin is also useful.[65]
Liver toxicity of ketamine also involves higher doses and repeated administration. In a group of chronic high dose ketamine users, the frequency of liver injury was reported to be about 10%. There are case reports of increased liver enzymes involving ketamine treatment of chronic pain.[65]

Dependence and tolerance[edit]
Although the incidence of ketamine dependence is unknown, some people who regularly use ketamine develop ketamine dependence. Animal experiments also confirm the risk of misuse.[25] Additionally, the rapid onset of effects following insufflation may increase the drug's recreational use potential. The short duration of effects promotes bingeing. Ketamine tolerance rapidly develops, even with repeated medical use, prompting the use of higher doses. Some daily users reported withdrawal symptoms, primarily anxiety, shaking, sweating, and palpitations, following the attempts to stop.[25] Cognitive deficits as well as increased dissociation and delusion symptoms were observed in frequent recreational users of ketamine.[67]

Interactions[edit]
Ketamine potentiates the sedative effects of propofol[68] and  midazolam.[69] Naltrexone potentiates psychotomimetic effects of a low dose of ketamine,[70] while lamotrigine[71] and nimodipine[72] decrease them. Clonidine reduces the salivation, heart rate and blood pressure increases during ketamine anesthesia and decreases the incidence of nightmares.[73]
Clinical observations suggest that benzodiazepines may diminish the antidepressant effects of ketamine.[74] Ketamine is frequently used to treat resistant depression as an add-on to a variety of antidepressants. Hence, it appears most conventional antidepressants can be safely combined with ketamine.[74]

Pharmacology[edit]
Pharmacodynamics[edit]
Mechanism of action[edit]
Antagonism of the NMDA receptor is responsible for the anesthetic, analgesic, and psychotomimetic effects of ketamine.[75][76] NMDA receptor antagonism results in analgesia by preventing central sensitization in dorsal horn neurons; in other words, ketamine's actions interfere with pain transmission in the spinal cord.[14]
The mechanism of antidepressant action of ketamine is uncertain. It is not clear whether NMDA receptor is solely responsible for this action or interactions with other receptors are also necessary. It is not clear whether ketamine alone is sufficient for the antidepressive action or its metabolites are also important.[75][77][78] In any case, it has been elucidated that acute blockade of NMDA receptors in the brain results in an activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA receptors), which in turn modulate a variety of downstream signaling pathways to influence neurotransmission in the limbic system and mediate antidepressant effects of NMDA receptor antagonists like ketamine.[51][77] Such downstream actions of this activation of AMPA receptors include upregulation of brain-derived neurotrophic factor (BDNF) and activation of its signaling receptor tropomyosin receptor kinase B (TrkB), activation of the mammalian target of rapamycin (mTOR) pathway, deactivation of glycogen synthase kinase 3 (GSK-3), and inhibition of the phosphorylation of the eukaryotic elongation factor 2 (eEF2) kinase.[51][77][79][80] In addition to blockade of the NMDA receptor, the active metabolite of ketamine hydroxynorketamine, which does not interact importantly with the NMDA receptor but nonetheless indirectly activates AMPA receptors similarly, may also or alternatively be involved in the rapid-onset antidepressant effects of ketamine.[77][78] Recent research has elucidated that an acute inhibition of the lateral habenula, a part of the brain in the limbic system that has been referred to as the "anti-reward center" (projecting to and inhibiting the mesolimbic reward pathway and modulating other limbic areas), may be involved in the antidepressant effects of ketamine.[77][81][82]
Ketamine is a mixture of equal amounts of two enantiomers: esketamine and arketamine. Esketamine is a more potent NMDA receptor antagonist and dissociative hallucinogen than arketamine.[11] Because of the hypothesis that NMDA receptor antagonism underlies the antidepressant effects of ketamine, esketamine was developed as an antidepressant.[11] However, multiple other NMDA receptor antagonists, including memantine, lanicemine, rislenemdaz, rapastinel, and 4-chlorokynurenine, have thus far failed to demonstrate sufficient effectiveness for depression.[11][83] Furthermore, animal research indicates that arketamine, the enantiomer with a weaker NMDA receptor antagonism, as well as (2R,6R)-hydroxynorketamine, the metabolite with negligible affinity for the NMDA receptor but a  potent alpha-7 nicotinic receptor antagonist may have antidepressive action.[11][84] It is now argued that NMDA receptor antagonism may not be responsible for the antidepressant effects of ketamine.[11][85][83]

Molecular targets[edit]

Ketamine and biological targets (with Ki below 100 μM)



Site
Value (μM)
Type
Action
Species
Ref


NMDA
0.25–0.66
Ki
Antagonist
Human
[86][87]


MOR
42
Ki
Antagonist
Human
[88]


MOR2
12.1

Ki

Antagonist
Human
[89]


KOR
2825

KiKi

AntagonistAgonist
Human
[88][90]



σ2
26
Ki
ND
Rat
[91]


D2
0.5>10
KiKi
AgonistND
Human
[92][87][93][94]


M1
45
Ki
ND
Human
[95]


α2β2
92
IC50
Antagonist
Human
[96]


α2β4
29
IC50
Antagonist
Human
[96]



α3β2
50
IC50
Antagonist
Human
[96]



α3β4
9.5
IC50
Antagonist
Human
[96]


α4β2
72
IC50
Antagonist
Human
[96]


α4β4
18
IC50
Antagonist
Human
[96]


α7
3.1
IC50
Antagonist
Rat
[84]


ERα
0.34
Ki
ND
Human
[97]


NET
82–291
IC50
Inhibitor
Human
[98][99]


DAT
63
Ki
Inhibitor
Rat
[98]


HCN1
8–16
EC50
Inhibitor
Mouse
[100]


The smaller the value, the stronger the interaction with the site.

Ketamine principally acts as an antagonist of the NMDA receptor, an ionotropic glutamate receptor.[101]  The S(+) and R(–) stereoisomers of ketamine bind to the dizocilpine site of the NMDA receptor with different affinities, the former showing approximately 3- to 4- fold greater affinity for the receptor than the latter. As a result, the S isomer is a more potent anesthetic and analgesic than its R counterpart.[102]
Ketamine may also interact with and inhibit the NMDAR via another allosteric site on the receptor.[103]
With a couple of exceptions ketamine actions at other receptors are far weaker than ketamine's antagonism of the NMDA receptor (see the activity table to the right).[6][104]
Although ketamine is a very weak ligand of the monoamine transporters (Ki > 60 μM), it has been suggested that it may interact with allosteric sites on the monoamine transporters to produce monoamine reuptake inhibition.[87] However, no functional inhibition (IC50) of the human monoamine transporters has been observed with ketamine or its metabolites at concentrations of up to 10,000 nM.[93][101] Moreover, animal studies and at least three human case reports have found no interaction between ketamine and the monoamine oxidase inhibitor (MAOI) tranylcypromine, which is of importance as the combination of a monoamine reuptake inhibitor with an MAOI can produce severe toxicity such as serotonin syndrome or hypertensive crisis.[105][106] Collectively, these findings shed doubt on the involvement of monoamine reuptake inhibition in the effects of ketamine in humans.[105][101][93][106] Ketamine has been found to increase dopaminergic neurotransmission in the brain, but instead of being due to dopamine reuptake inhibition, this may be via indirect/downstream mechanisms, namely through antagonism of the NMDA receptor.[101][93]
Whether ketamine is an agonist of D2 receptors is controversial. Early research by Philip Seeman's group found ketamine to be a D2 partial agonist with the potency similar to that of its NMDA receptor antagonism.[92][107][108] However, later studies by different researchers found the affinity of ketamine of >10 μM for the regular human and rat D2 receptors,[87][93][94] Moreover, whereas D2 receptor agonists like bromocriptine are able to rapidly and powerfully suppress prolactin secretion,[109] subanesthetic doses of ketamine have not been found to do this in humans and in fact have been found to dose-dependently increase prolactin levels.[110][111] Imaging studies have shown mixed results on inhibition of striatal [11C] raclopride binding by ketamine in humans, with some studies finding a significant decrease and others finding no such effect.[112] However, changes in [11C] raclopride binding may be due to changes in dopamine concentrations induced by ketamine rather than binding of ketamine to the D2 receptor.[112]

Relationships between levels and effects[edit]
Dissociation and psychotomimetic effects are reported in patients treated with ketamine at plasma concentrations of around 100 to 250 ng/mL (0.42–1.1 μM).[75] The typical intravenous antidepressant dosage of ketamine used to treat depression is low and results in maximal plasma concentrations of 70 to 200 ng/mL (0.29–0.84 μM).[50] At similar plasma concentrations (70 to 160 ng/mL; 0.29–0.67 μM) it also shows analgesic effects.[50] In 1–5 minutes after inducing anesthesia by a rapid intravenous injection of ketamine, its plasma concentration reaches as high as 60–110 μM.[113][114] When the anesthesia was maintained using nitrous oxide together with continuous injection of ketamine, the ketamine concentration stabilized at about 9.3 μM.[113] In an experiment with purely ketamine anesthesia, patients began to awaken once the plasma level of ketamine decreased to about 2,600 ng/mL (11 μM) and became oriented in place and time when the level was down to 1,000 ng/mL (4 μM).[115] In a single-case study, the concentration of ketamine in cerebrospinal fluid, a proxy for the brain concentration, during anesthesia varied between 2.8 and 6.5 μM and was about 40% lower than in plasma.[116]

Pharmacokinetics[edit]
Ketamine can be absorbed by many different routes due to both its water and lipid solubility. Intravenous ketamine bioavailability is 100% by definition, intramuscular injection bioavailability is slightly lower at 93%,[6] and epidural bioavailability is 77%.[9] Subcutaneous bioavailability has never been measured but is presumed to be high.[8] Among the less invasive routes, intranasal has the highest bioavailability (45–50%)[6][10] and oral – the lowest (16–20%).[6][10] Sublingual and rectal bioavailabilities are intermediate at about 25–50%.[6][11][10]
After absorption ketamine is rapidly distributed into the brain and other tissues.[76] The plasma protein binding of ketamine is variable at 23 to 47%.[12]

  Major routes of ketamine metabolism.[75]
In the body ketamine undergoes extensive metabolism. It is biotransformed  by CYP3A4 and CYP2B6 isoenzymes into norketamine, which, in turn, is converted by CYP2A6 and CYP2B6 into hydroxynorketamine and dehydronorketamine.[75] Low oral bioavailability of ketamine is due to the first-pass effect and, possibly, ketamine intestinal metabolism by CYP3A4.[17] As a result, norketamine plasma levels are several-fold higher than ketamine following oral administration, and norketamine may play a role in anesthetic and analgesic action of oral ketamine.[6][17] This also explains why oral ketamine levels are independent of CYP2B6 activity, unlike subcutaneous ketamine levels.[17][117]
After an intravenous injection of tritium-labelled ketamine, 91% of the radioactivity is recovered from urine and 3% from the feces.[15] The medication is excreted mostly in the form of metabolites, with only 2% remaining unchanged. Conjugated hydroxylated derivatives of ketamine (80%) followed by dehydronorketamine (16%) are the most prevalent metabolites detected in urine.[24]

Chemistry[edit]
Synthesis[edit]
2-chlorobenzonitrile is reacted with the Grignard reagent cyclopentylmagnesium bromide to give (2-chlorophenyl)(cyclopentyl)methanone. This is then brominated using bromine to form the corresponding bromoketone, which is then reacted with methylamine in an aqueous solution to form the methylimino derivative, 1-(2-Chloro-N-methylbenzimidoyl)cyclopentanol, with hydrolysis of the tertiary bromine atom. This final intermediate is then heated in decalin or another suitable high-boiling solvent, upon which a ring-expansion rearrangement occurs, forming ketamine.

  Preparation of Ketamine.[118]
Structure[edit]
.mw-parser-output .tmulti .thumbinner{display:flex;flex-direction:column}.mw-parser-output .tmulti .trow{display:flex;flex-direction:row;clear:left;flex-wrap:wrap;width:100%;box-sizing:border-box}.mw-parser-output .tmulti .tsingle{margin:1px;float:left}.mw-parser-output .tmulti .theader{clear:both;font-weight:bold;text-align:center;align-self:center;background-color:transparent;width:100%}.mw-parser-output .tmulti .thumbcaption{background-color:transparent}.mw-parser-output .tmulti .text-align-left{text-align:left}.mw-parser-output .tmulti .text-align-right{text-align:right}.mw-parser-output .tmulti .text-align-center{text-align:center}@media all and (max-width:720px){.mw-parser-output .tmulti .thumbinner{width:100%!important;box-sizing:border-box;max-width:none!important;align-items:center}.mw-parser-output .tmulti .trow{justify-content:center}.mw-parser-output .tmulti .tsingle{float:none!important;max-width:100%!important;box-sizing:border-box;text-align:center}.mw-parser-output .tmulti .tsingle .thumbcaption{text-align:left}.mw-parser-output .tmulti .trow>.thumbcaption{text-align:center}}(S)-ketamine(R)-ketamine
In chemical structure, ketamine is an arylcyclohexylamine derivative. Ketamine is a chiral compound. The more active enantiomer, esketamine (S-ketamine), is also available for medical use under the brand name Ketanest S,[119] while the less active enantiomer, arketamine (R-ketamine), has never been marketed as an enantiopure drug for clinical use. While S-ketamine is more effective as an analgesic and anesthetic through NMDA receptor antagonism, R-ketamine produces longer-lasting effects as an antidepressant.
The optical rotation of a given enantiomer of ketamine can vary between its salts and free base form. The free base form of (S)‑ketamine exhibits dextrorotation and is therefore labelled (S)‑(+)‑ketamine. However, its hydrochloride salt shows levorotation and is thus labelled (S)‑(−)‑ketamine hydrochloride.[120]

Detection[edit]
Ketamine may be quantitated in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest or to assist in a medicolegal death investigation. Blood or plasma ketamine concentrations are usually in a range of 0.5–5.0 mg/L in persons receiving the drug therapeutically (during general anesthesia), 1–2 mg/L in those arrested for impaired driving and 3–20 mg/L in victims of acute fatal overdosage. Urine is often the preferred specimen for routine drug use monitoring purposes. The presence of norketamine, a pharmacologically active metabolite, is useful for confirmation of ketamine ingestion.[121][122][123]

History[edit]
Ketamine was first synthesized in 1962 by Calvin L. Stevens, a professor of chemistry at Wayne State University and a Parke-Davis consultant. It was known by the developmental code name CI-581. After promising preclinical research in animals, ketamine was tested in human prisoners in 1964.[24] These investigations demonstrated ketamine's short duration of action and reduced behavioral toxicity made it a favorable choice over phencyclidine (PCP) as an anesthetic.[124] The researchers were going to call the state of ketamine anesthesia "dreaming" but Parke-Davis did not like it. Hearing about this problem and about the "disconnected" appearance of the patients, the wife of one of the pharmacologists working on ketamine, Edward Domino, suggested "dissociative anesthesia".[24] Following FDA approval in 1970, ketamine anesthesia was first given to American soldiers during the Vietnam War.[125]
The discovery of antidepressive action of ketamine in 2000[126] has been described as the single most important advance in the treatment of depression in over 50 years.[53][11] It has sparked interest in NMDA receptor antagonists for depression, and has shifted the direction of antidepressant research and development.[127]

Society and culture[edit]
Main article: Ketamine in society and culture
Legal status[edit]
While ketamine is legally marketed in many countries worldwide,[128] it is also a controlled substance in many countries.[6]

In Australia, ketamine is listed as a schedule 8 controlled drug under the Poisons Standard (October 2015).[129]
In Canada, ketamine is classified as a Schedule I narcotic, since 2005.[130]
In December 2013, the government of India, in response to rising recreational use and the use of ketamine as a date rape drug, has added it to Schedule X of the Drug and Cosmetics Act requiring a special license for sale and maintenance of records of all sales for two years.[131][132]
In the United Kingdom, it became labeled a Class B drug on 12 February 2014.[133][134]
The increase in recreational use prompted ketamine to be placed in Schedule III of the United States Controlled Substance Act in August 1999.[135]
Recreational use[edit]
Main article: Ketamine in society and culture § Recreational use
At subanesthetic doses ketamine produces a dissociative state, characterised by a sense of detachment from one's physical body and the external world that is known as depersonalization and derealization.[136] At sufficiently high doses, users may experience what is called the "K-hole", a state of dissociation with visual and auditory hallucinations similar to the effects of LSD.[137] John C. Lilly, Marcia Moore, D. M. Turner, and David Woodard (amongst others) have written extensively about their own entheogenic use of, and psychonautic experiences with, ketamine.[138] Turner died prematurely due to drowning during presumed unsupervised ketamine use.[139] In 2006 the Russian edition of Adam Parfrey's Apocalypse Culture II was banned and destroyed by authorities owing to its inclusion of an essay by Woodard about the entheogenic use of, and psychonautic experiences with, ketamine.[140]: 288–295 
Recreational ketamine use has been implicated in deaths globally, with more than 90 deaths in England and Wales in the years of 2005–2013.[141] They include accidental poisonings, drownings, traffic accidents, and suicides.[141] The majority of deaths were among young people.[142] Because of its ability to cause confusion and amnesia, ketamine has been used for date rape.[143][125]

Veterinary medicine[edit]
In veterinary anaesthesia, ketamine is often used for its anaesthetic and analgesic effects on cats,[144] dogs,[145] rabbits, rats, and other small animals.[146][147] It is frequently used in induction and anaesthetic maintenance in horses. It is an important part of the "rodent cocktail", a mixture of drugs used for anaesthetising rodents.[148] Veterinarians often use ketamine with sedative drugs to produce balanced anaesthesia and analgesia, and as a constant-rate infusion to help prevent pain wind-up. Ketamine is also used to manage pain among large animals. It is the primary intravenous anaesthetic agent used in equine surgery, often in conjunction with detomidine and thiopental, or sometimes guaifenesin.[149]
Ketamine appears not to produce sedation or anaesthesia in snails. Instead, it appears to have an excitatory effect.[150]

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 159–. ISBN 978-94-011-4439-1. Archived from the original on 11 April 2017.

^ Jump up to: a b "Ketamine (Ketalar) Use During Pregnancy". Drugs.com. 22 November 2019. Retrieved 18 May 2020.

^ Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders".  In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 374–375. ISBN 978-0-07-148127-4. Phencyclidine (PCP or angel dust) and ketamine (also known as special K) are structurally related drugs... their reinforcing properties and risks related to compulsive abuse

^ Bell RF, Eccleston C, Kalso EA (June 2017). "Ketamine as an adjuvant to opioids for cancer pain" (PDF). The Cochrane Database of Systematic Reviews. 6 (9): CD003351. doi:10.1002/14651858.CD003351.pub3. PMC 6481583. PMID 28657160.

^ Moyse DW, Kaye AD, Diaz JH, Qadri MY, Lindsay D, Pyati S (March 2017). "Perioperative Ketamine Administration for Thoracotomy Pain". Pain Physician. 20 (3): 173–184. PMID 28339431.

^ Jump up to: a b c d e f g h i j k l m n o Mathew SJ, Zarate Jr CA (25 November 2016). Ketamine for Treatment-Resistant Depression: The First Decade of Progress. Springer. pp. 8–10, 14–22. ISBN 978-3-319-42925-0. Archived from the original on 8 September 2017.

^ Brayfield, A, ed. (9 January 2017). "Ketamine Hydrochloride: Martindale: The Complete Drug Reference". MedicinesComplete. London, UK: Pharmaceutical Press. Retrieved 24 August 2017.

^ Jump up to: a b Jianren Mao (19 April 2016). Opioid-Induced Hyperalgesia. CRC Press. pp. 127–. ISBN 978-1-4200-8900-4. Archived from the original on 8 September 2017.

^ Jump up to: a b Pascal Kintz (22 March 2014). Toxicological Aspects of Drug-Facilitated Crimes. Elsevier Science. pp. 87–. ISBN 978-0-12-416969-2. Archived from the original on 8 September 2017.

^ Jump up to: a b c d e f g h i Marland S, Ellerton J, Andolfatto G, Strapazzon G, Thomassen O, Brandner B, Weatherall A, Paal P (June 2013). "Ketamine: use in anesthesia". CNS Neurosci Ther. 19 (6): 381–9. doi:10.1111/cns.12072. PMC 6493613. PMID 23521979.

^ Jump up to: a b c d e f g h Hashimoto K (October 2019). "Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective". Psychiatry and Clinical Neurosciences. 73 (10): 613–627. doi:10.1111/pcn.12902. PMC 6851782. PMID 31215725.

^ Jump up to: a b Dayton PG, Stiller RL, Cook DR, Perel JM (1983). "The binding of ketamine to plasma proteins: emphasis on human plasma". Eur J Clin Pharmacol. 24 (6): 825–31. doi:10.1007/BF00607095. PMID 6884418. S2CID 807011.

^ Jump up to: a b c d e f g h Sinner B, Graf BM (2008). "Ketamine".  In Schüttler J, Schwilden H (eds.). Modern Anesthetics. Handbook of Experimental Pharmacology. Vol. 182. pp. 313–33. doi:10.1007/978-3-540-74806-9_15. ISBN 978-3-540-72813-9. PMID 18175098.

^ Jump up to: a b c d e f g h Quibell R, Prommer EE, Mihalyo M, Twycross R, Wilcock A (March 2011). "Ketamine*". Journal of Pain and Symptom Management (Therapeutic Review). 41 (3): 640–9. doi:10.1016/j.jpainsymman.2011.01.001. PMID 21419322.

^ Jump up to: a b c Chang T, Glazko AJ (1974). "Biotransformation and disposition of ketamine". Int Anesthesiol Clin. 12 (2): 157–77. doi:10.1097/00004311-197412020-00018. PMID 4603048. S2CID 30723730.

^ Hijazi Y, Boulieu R (July 2002). "Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes". Drug Metabolism and Disposition. 30 (7): 853–8. doi:10.1124/dmd.30.7.853. PMID 12065445. S2CID 15787750.

^ Jump up to: a b c d Rao LK, Flaker AM, Friedel CC, Kharasch ED (December 2016). "Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance". Anesthesiology. 125 (6): 1103–1112. doi:10.1097/ALN.0000000000001392. PMID 27763887. S2CID 41380105.

^ Sass W, Fusari S (1977). "Ketamine". Analytical Profiles of Drug Substances, volume 6. Analytical Profiles of Drug Substances. Vol. 6. Academic Press. pp. 297–322. doi:10.1016/S0099-5428(08)60347-0. ISBN 9780122608063.

^ Jump up to: a b c Green SM, Roback MG, Kennedy RM, Krauss B (May 2011). "Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update". Annals of Emergency Medicine. 57 (5): 449–61. doi:10.1016/j.annemergmed.2010.11.030. PMID 21256625.

^ Jump up to: a b Zhang K, Hashimoto K (January 2019). "An update on ketamine and its two enantiomers as rapid-acting antidepressants". Expert Review of Neurotherapeutics. 19 (1): 83–92. doi:10.1080/14737175.2019.1554434. PMID 30513009. S2CID 54628949.

^ Jump up to: a b c d Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S, Beauchamp S (December 2020). "A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019". J Affect Disord. 277: 831–841. doi:10.1016/j.jad.2020.09.007. PMID 33065824. S2CID 223557698.

^ Jump up to: a b c d Swainson J, McGirr A, Blier P, Brietzke E, Richard-Devantoy S, Ravindran N, Blier J, Beaulieu S, Frey BN, Kennedy SH, McIntyre RS, Milev RV, Parikh SV, Schaffer A, Taylor VH, Tourjman V, van Ameringen M, Yatham LN, Ravindran AV, Lam RW (November 2020). "The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur". Can J Psychiatry. 66 (2): 113–125. doi:10.1177/0706743720970860. PMC 7918868. PMID 33174760.

^ Jump up to: a b Bobo WV, Riva-Posse P, Goes FS, Parikh SV (April 2020). "Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine". Focus (Am Psychiatr Publ). 18 (2): 181–192. doi:10.1176/appi.focus.20190048. PMC 7587874. PMID 33162856.

^ Jump up to: a b c d Domino EF (September 2010). "Taming the ketamine tiger. 1965". Anesthesiology. 113 (3): 678–84. doi:10.1097/ALN.0b013e3181ed09a2. PMID 20693870.

^ Jump up to: a b c Morgan CJ, Curran HV (January 2012). "Ketamine use: a review". Addiction. 107 (1): 27–38. doi:10.1111/j.1360-0443.2011.03576.x. PMID 21777321. S2CID 11064759.

^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06.

^ "Ketamine Injection". Drugs.com. Archived from the original on 10 December 2014. Retrieved 1 December 2014.

^ Jump up to: a b Rosenbaum SB, Gupta V, Palacios JL (2020). "Ketamine". StatPearls. StatPearls Publishing. PMID 29262083. Retrieved 5 March 2020.

^ Heshmati F, Zeinali MB, Noroozinia H, Abbacivash R, Mahoori A (December 2003). "Use of ketamine in severe status asthmaticus in intensive care unit". Iranian Journal of Allergy, Asthma, and Immunology. 2 (4): 175–80. PMID 17301376. Archived from the original on 6 October 2014.

^ Adams HA (December 1997). "[S-(+)-ketamine. Circulatory interactions during total intravenous anesthesia and analgesia-sedation]" [S-(+)-ketamine. Circulatory interactions during total intravenous anesthesia and analgesia-sedation]. Der Anaesthesist (in German). 46 (12): 1081–7. doi:10.1007/s001010050510. PMID 9451493.

^ Wong JJ, Lee JH, Turner DA, Rehder KJ (August 2014). "A review of the use of adjunctive therapies in severe acute asthma exacerbation in critically ill children". Expert Review of Respiratory Medicine. 8 (4): 423–41. doi:10.1586/17476348.2014.915752. PMID 24993063. S2CID 31435021.

^ Jump up to: a b c d Barrett W, Buxhoeveden M, Dhillon S (October 2020). "Ketamine: a versatile tool for anesthesia and analgesia". Current Opinion in Anesthesiology. 33 (5): 633–638. doi:10.1097/ACO.0000000000000916. PMID 32826629. S2CID 221236545.

^ Cohen L, Athaide V, Wickham ME, Doyle-Waters MM, Rose NG, Hohl CM (January 2015). "The effect of ketamine on intracranial and cerebral perfusion pressure and health outcomes: a systematic review". Annals of Emergency Medicine. 65 (1): 43–51.e2. doi:10.1016/j.annemergmed.2014.06.018. PMID 25064742.

^ Jump up to: a b c Kurdi MS, Theerth KA, Deva RS (September 2014). "Ketamine: Current applications in anesthesia, pain, and critical care". Anesthesia: Essays and Researches. 8 (3): 283–90. doi:10.4103/0259-1162.143110. PMC 4258981. PMID 25886322.

^ Mion G (September 2017). "History of anaesthesia: The ketamine story - past, present and future". Eur J Anaesthesiol. 34 (9): 571–575. doi:10.1097/EJA.0000000000000638. PMID 28731926. S2CID 27536846.

^ Nickson C (7 August 2013). "Intubation, Hypotension and Shock". Life in the Fastlane (blog). Critical Care Compendium. Archived from the original on 9 February 2014. Retrieved 10 April 2014.[unreliable medical source?]

^ Manley G, Knudson MM, Morabito D, Damron S, Erickson V, Pitts L (October 2001). "Hypotension, hypoxia, and head injury: frequency, duration, and consequences". Archives of Surgery. 136 (10): 1118–23. doi:10.1001/archsurg.136.10.1118. PMID 11585502.

^ Hemmingsen C, Nielsen JE (November 1991). "Intravenous ketamine for prevention of severe hypotension during spinal anaesthesia". Acta Anaesthesiologica Scandinavica. 35 (8): 755–7. doi:10.1111/j.1399-6576.1991.tb03385.x. PMID 1763596. S2CID 1324453.

^ Wong DH, Jenkins LC (May 1975). "The cardiovascular effects of ketamine in hypotensive states". Canadian Anaesthetists' Society Journal. 22 (3): 339–48. doi:10.1007/BF03004843. PMID 1139377.

^ Goyal S, Agrawal A (May 2013). "Ketamine in status asthmaticus: A review". Indian Journal of Critical Care Medicine. 17 (3): 154–61. doi:10.4103/0972-5229.117048. PMC 3777369. PMID 24082612.

^ Jump up to: a b c Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, Bhatia A, Davis FN, Hooten WM, Cohen SP (July 2018). "Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists". Reg Anesth Pain Med. 43 (5): 456–466. doi:10.1097/AAP.0000000000000806. PMC 6023582. PMID 29870457.

^ Sin B, Ternas T, Motov SM (March 2015). "The use of subdissociative-dose ketamine for acute pain in the emergency department". Academic Emergency Medicine. 22 (3): 251–7. doi:10.1111/acem.12604. PMID 25716117. S2CID 24658476.

^ Svenson J, Biedermann M (2011). "Ketamine: a unique drug with several potential uses in the prehospital setting". Journal of Paramedic Practice. 3 (10): 552–556. doi:10.12968/jpar.2011.3.10.552.

^ Karlow N, Schlaepfer CH, Stoll CR, Doering M, Carpenter CR, Colditz GA,  et al. (October 2018). "A Systematic Review and Meta-analysis of Ketamine as an Alternative to Opioids for Acute Pain in the Emergency Department". Academic Emergency Medicine. 25 (10): 1086–1097. doi:10.1111/acem.13502. PMID 30019434.

^ Radvansky BM, Shah K, Parikh A, Sifonios AN, Le V, Eloy JD (2015). "Role of ketamine in acute postoperative pain management: a narrative review". BioMed Research International. 2015: 749837. doi:10.1155/2015/749837. PMC 4606413. PMID 26495312.

^ Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L (2011). "A comprehensive review of opioid-induced hyperalgesia". Pain Physician. 14 (2): 145–61. doi:10.36076/ppj.2011/14/145. PMID 21412369.

^ Zhou Y, Mannan A, Han Y, Liu H, Guan HL, Gao X,  et al. (December 2019). "Efficacy and safety of prophylactic use of ketamine for prevention of postanesthetic shivering: a systematic review and meta analysis". BMC Anesthesiology. 19 (1): 245. doi:10.1186/s12871-019-0910-8. PMC 6937868. PMID 31888509.

^ Jump up to: a b c d e Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, Viscusi ER, Narouze S, Davis FN, Ritchie EC, Lubenow TR, Hooten WM (July 2018). "Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists". Reg Anesth Pain Med. 43 (5): 521–546. doi:10.1097/AAP.0000000000000808. PMC 6023575. PMID 29870458.

^ Elia N, Tramèr MR (January 2005). "Ketamine and postoperative pain—a quantitative systematic review of randomised trials". Pain. 113 (1–2): 61–70. doi:10.1016/j.pain.2004.09.036. PMID 15621365. S2CID 25925720.

^ Jump up to: a b c Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF,  et al. (April 2017). "A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders". JAMA Psychiatry. 74 (4): 399–405. doi:10.1001/jamapsychiatry.2017.0080. PMID 28249076. S2CID 28320520.

^ Jump up to: a b c d Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sánchez E, Gutiérrez-Rojas L, Meana JJ (May 2018). "Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review". CNS Drugs. 32 (5): 411–420. doi:10.1007/s40263-018-0519-3. PMID 29736744. S2CID 13679905.

^ Sanacora G, Katz R (July 2018). "Ketamine: A Review for Clinicians". Focus. American Psychiatric Association Publishing. 16 (3): 243–250. doi:10.1176/appi.focus.20180012. PMC 6493090. PMID 31975918.

^ Jump up to: a b Singh I, Morgan C, Curran V, Nutt D, Schlag A, McShane R (May 2017). "Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight". The Lancet. Psychiatry. 4 (5): 419–426. doi:10.1016/S2215-0366(17)30102-5. hdl:10871/30208. PMID 28395988.

^ Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW, Loo C, Cipriani A, Hawton K (January 2020). "Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials". Aust N Z J Psychiatry. 54 (1): 29–45. doi:10.1177/0004867419883341. PMID 31729893. S2CID 208035394.

^ Bahji A, Vazquez GH, Zarate CA (January 2021). "Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis". J Affect Disord. 278: 542–555. doi:10.1016/j.jad.2020.09.071. ISSN 0165-0327. PMC 7704936. PMID 33022440.

^ Wilkowska A, Szałach Ł, Cubała WJ (12 November 2020). "Ketamine in Bipolar Disorder: A Review". Neuropsychiatric Disease and Treatment. 16: 2707–2717. doi:10.2147/NDT.S282208. PMC 7670087. PMID 33209026.

^ Jansen K (2001). Ketamine: Dreams and Realities. Multidisciplinary Association for Psychedelic Studies. p. 122. ISBN 978-0-9660019-3-8.

^ Peinkhofer C, Dreier JP, Kondziella D (July 2019). "Semiology and Mechanisms of Near-Death Experiences". Current Neurology and Neuroscience Reports. 19 (9): 62. doi:10.1007/s11910-019-0983-2. PMID 31352520.

^ Martial C, Cassol H, Charland-Verville V, Pallavicini C, Sanz C, Zamberlan F,  et al. (March 2019). "Neurochemical models of near-death experiences: A large-scale study based on the semantic similarity of written reports". Consciousness and Cognition. 69: 52–69. doi:10.1016/j.concog.2019.01.011. PMID 30711788.

^ Gomes D, Pimentel J, Bentes C, Aguiar de Sousa D, Antunes AP, Alvarez A, Silva ZC (October 2018). "Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus". Acta Médica Portuguesa. 31 (10): 598–605. doi:10.20344/amp.9679. PMID 30387431.

^ Rosati A, De Masi S, Guerrini R (November 2018). "Ketamine for Refractory Status Epilepticus: A Systematic Review". CNS Drugs. 32 (11): 997–1009. doi:10.1007/s40263-018-0569-6. PMID 30232735. S2CID 52302073.

^ Jump up to: a b c d e Strayer RJ, Nelson LS (November 2008). "Adverse events associated with ketamine for procedural sedation in adults". The American Journal of Emergency Medicine. 26 (9): 985–1028. doi:10.1016/j.ajem.2007.12.005. PMID 19091264. Archived from the original on 8 September 2017.

^ Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, Kraus C, Kadriu B, Zarate CA, Park LT (February 2020). "Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression". J Affect Disord. 263: 568–575. doi:10.1016/j.jad.2019.11.028. PMC 8457026. PMID 31791675.

^ Smith HS (2010). "Ketamine-induced urologic insult (KIUI)". Pain Physician. 13 (6): E343–6. doi:10.36076/ppj.2010/13/E343. PMID 21102971.

^ Jump up to: a b c d Castellani D, Pirola GM, Gubbiotti M, Rubilotta E, Gudaru K, Gregori A, Dellabella M (April 2020). "What urologists need to know about ketamine-induced uropathy: A systematic review". Neurourol Urodyn. 39 (4): 1049–1062. doi:10.1002/nau.24341. PMID 32212278. S2CID 214643776.

^ Middela S, Pearce I (January 2011). "Ketamine-induced vesicopathy: a literature review". International Journal of Clinical Practice. 65 (1): 27–30. doi:10.1111/j.1742-1241.2010.02502.x. PMID 21155941. S2CID 25034266.

^ Morgan CJ, Muetzelfeldt L, Curran HV (January 2010). "Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study". Addiction. 105 (1): 121–33. doi:10.1111/j.1360-0443.2009.02761.x. PMID 19919593.

^ Hui TW, Short TG, Hong W, Suen T, Gin T, Plummer J (March 1995). "Additive interactions between propofol and ketamine when used for anesthesia induction in female patients". Anesthesiology. 82 (3): 641–8. doi:10.1097/00000542-199503000-00005. PMID 7879932. S2CID 24005549.

^ Hong W, Short TG, Hui TW (December 1993). "Hypnotic and anesthetic interactions between ketamine and midazolam in female patients". Anesthesiology. 79 (6): 1227–32. doi:10.1097/00000542-199312000-00013. PMID 8267198. S2CID 12246068.

^ Krystal JH, Madonick S, Perry E, Gueorguieva R, Brush L, Wray Y, Belger A, D'Souza DC (August 2006). "Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism". Neuropsychopharmacology. 31 (8): 1793–800. doi:10.1038/sj.npp.1300994. PMID 16395307.

^ Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH (March 2000). "Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists". Arch Gen Psychiatry. 57 (3): 270–6. doi:10.1001/archpsyc.57.3.270. PMID 10711913.

^ Krupitsky EM, Burakov AM, Romanova TN, Grinenko NI, Grinenko AY, Fletcher J, Petrakis IL, Krystal JH (December 2001). "Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists". Neuropsychopharmacology. 25 (6): 936–47. doi:10.1016/S0893-133X(01)00346-3. PMID 11750186.

^ Handa F, Tanaka M, Nishikawa T, Toyooka H (February 2000). "Effects of oral clonidine premedication on side effects of intravenous ketamine anesthesia: a randomized, double-blind, placebo-controlled study". J Clin Anesth. 12 (1): 19–24. doi:10.1016/s0952-8180(99)00131-2. PMID 10773503.

^ Jump up to: a b Andrade C (July 2017). "Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions". The Journal of Clinical Psychiatry. 78 (7): e858–e861. doi:10.4088/JCP.17f11802. PMID 28858450.

^ Jump up to: a b c d e Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EF, Albuquerque EX, Thomas CJ, Zarate CA, Gould TD (July 2018). "Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms". Pharmacol Rev. 70 (3): 621–660. doi:10.1124/pr.117.015198. PMC 6020109. PMID 29945898.

^ Jump up to: a b Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI (September 2016). "Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy". Clin Pharmacokinet. 55 (9): 1059–77. doi:10.1007/s40262-016-0383-6. PMID 27028535. S2CID 5078489.

^ Jump up to: a b c d e Zanos P, Gould TD (April 2018). "Mechanisms of ketamine action as an antidepressant". Molecular Psychiatry. 23 (4): 801–811. doi:10.1038/mp.2017.255. PMC 5999402. PMID 29532791.

^ Jump up to: a b Zanos P, Thompson SM, Duman RS, Zarate CA, Gould TD (March 2018). "Convergent Mechanisms Underlying Rapid Antidepressant Action". CNS Drugs. 32 (3): 197–227. doi:10.1007/s40263-018-0492-x. PMC 6005380. PMID 29516301.

^ Björkholm C, Monteggia LM (March 2016). "BDNF – a key transducer of antidepressant effects". Neuropharmacology. 102: 72–9. doi:10.1016/j.neuropharm.2015.10.034. PMC 4763983. PMID 26519901.

^ Castrén E, Kojima M (January 2017). "Brain-derived neurotrophic factor in mood disorders and antidepressant treatments". Neurobiology of Disease. 97 (Pt B): 119–126. doi:10.1016/j.nbd.2016.07.010. hdl:10138/311483. PMID 27425886. S2CID 644350.

^ Kim D, Cheong E, Shin HS (June 2018). "Overcoming Depression by Inhibition of Neural Burst Firing". Neuron. 98 (5): 878–879. doi:10.1016/j.neuron.2018.05.032. PMID 29879390.

^ Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, Hu H (February 2018). "Ketamine blocks bursting in the lateral habenula to rapidly relieve depression". Nature. 554 (7692): 317–322. Bibcode:2018Natur.554..317Y. doi:10.1038/nature25509. PMID 29446381. S2CID 3334820.

^ Jump up to: a b Garay R, Zarate CA, Cavero I, Kim YK, Charpeaud T, Skolnick P (October 2018). "The development of glutamate-based antidepressants is taking longer than expected". Drug Discovery Today. 23 (10): 1689–1692. doi:10.1016/j.drudis.2018.02.006. PMC 6211562. PMID 29501913.

^ Jump up to: a b Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, Rosenberg A, Tran T, Xiao Y, Zarate CA, Wainer IW (January 2013). "Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors". Eur J Pharmacol. 698 (1–3): 228–34. doi:10.1016/j.ejphar.2012.11.023. PMC 3534778. PMID 23183107.

^ "Arketamine – Jiangsu Hengrui Medicine – AdisInsight".

^ Morris PJ, Moaddel R, Zanos P, Moore CE, Gould TD, Zarate CA, Thomas CJ (September 2017). "Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites". Organic Letters. 19 (17): 4572–4575. doi:10.1021/acs.orglett.7b02177. PMC 5641405. PMID 28829612.

^ Jump up to: a b c d Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2013). "The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor". PLOS ONE. 8 (3): e59334. Bibcode:2013PLoSO...859334R. doi:10.1371/journal.pone.0059334. PMC 3602154. PMID 23527166.

^ Jump up to: a b Hirota K, Okawa H, Appadu BL, Grandy DK, Devi LA, Lambert DG (January 1999). "Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells". Anesthesiology. 90 (1): 174–82. doi:10.1097/00000542-199901000-00023. PMID 9915326.

^ Hirota K, Sikand KS, Lambert DG (1999). "Interaction of ketamine with mu2 opioid receptors in SH-SY5Y human neuroblastoma cells". Journal of Anesthesia. 13 (2): 107–9. doi:10.1007/s005400050035. PMID 14530949. S2CID 9322174.

^ Nemeth CL, Paine TA, Rittiner JE, Béguin C, Carroll FI, Roth BL, Cohen BM, Carlezon WA (June 2010). "Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats". Psychopharmacology (Berl). 210 (2): 263–74. doi:10.1007/s00213-010-1834-7. PMC 2869248. PMID 20358363.

^ Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR (April 2012). "Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo". Eur Neuropsychopharmacol. 22 (4): 308–17. doi:10.1016/j.euroneuro.2011.08.002. PMID 21911285. S2CID 24494428.

^ Jump up to: a b Kapur S, Seeman P (2002). "NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia". Molecular Psychiatry. 7 (8): 837–44. doi:10.1038/sj.mp.4001093. PMID 12232776.

^ Jump up to: a b c d e Can A, Zanos P, Moaddel R, Kang HJ, Dossou KS, Wainer IW,  et al. (October 2016). "Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters". The Journal of Pharmacology and Experimental Therapeutics. 359 (1): 159–70. doi:10.1124/jpet.116.235838. PMC 5034706. PMID 27469513.

^ Jump up to: a b Jordan S, Chen R, Fernalld R, Johnson J, Regardie K, Kambayashi J,  et al. (July 2006). "In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D2 receptors". European Journal of Pharmacology. 540 (1–3): 53–6. doi:10.1016/j.ejphar.2006.04.026. PMID 16730695.

^ Hirota K, Hashimoto Y, Lambert DG (December 2002). "Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells". Anesth Analg. 95 (6): 1607–10, table of contents. doi:10.1097/00000539-200212000-00025. PMID 12456425. S2CID 25643394.

^ Jump up to: a b c d e f Yamakura T, Chavez-Noriega LE, Harris RA (April 2000). "Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine". Anesthesiology. 92 (4): 1144–53. doi:10.1097/00000542-200004000-00033. PMID 10754635. S2CID 23651917.

^ Ho MF, Correia C, Ingle JN, Kaddurah-Daouk R, Wang L, Kaufmann SH, Weinshilboum RM (June 2018). "Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression". Biochemical Pharmacology. 152: 279–292. doi:10.1016/j.bcp.2018.03.032. PMC 5960634. PMID 29621538.

^ Jump up to: a b Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S, Tohyama M (March 1998). "Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells". Anesthesiology. 88 (3): 768–74. doi:10.1097/00000542-199803000-00029. PMID 9523822. S2CID 30159489.

^ Zhao Y, Sun L (November 2008). "Antidepressants modulate the in vitro inhibitory effects of propofol and ketamine on norepinephrine and serotonin transporter function". J Clin Neurosci. 15 (11): 1264–9. doi:10.1016/j.jocn.2007.11.007. PMC 2605271. PMID 18815045.

^ Chen X, Shu S, Bayliss DA (January 2009). "HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine". The Journal of Neuroscience. 29 (3): 600–9. doi:10.1523/JNEUROSCI.3481-08.2009. PMC 2744993. PMID 19158287.

^ Jump up to: a b c d Tyler MW, Yourish HB, Ionescu DF, Haggarty SJ (June 2017). "Classics in Chemical Neuroscience: Ketamine". ACS Chemical Neuroscience. 8 (6): 1122–1134. doi:10.1021/acschemneuro.7b00074. PMID 28418641.

^ Hirota K, Lambert DG (October 1996). "Ketamine: its mechanism(s) of action and unusual clinical uses". British Journal of Anaesthesia. 77 (4): 441–4. doi:10.1093/bja/77.4.441. PMID 8942324.

^ Orser BA, Pennefather PS, MacDonald JF (April 1997). "Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors". Anesthesiology. 86 (4): 903–17. doi:10.1097/00000542-199704000-00021. PMID 9105235. S2CID 2164198.

^ Lodge D, Mercier MS (September 2015). "Ketamine and phencyclidine: the good, the bad and the unexpected". British Journal of Pharmacology. 172 (17): 4254–76. doi:10.1111/bph.13222. PMC 4556466. PMID 26075331.

^ Jump up to: a b Kraus C, Rabl U, Vanicek T, Carlberg L, Popovic A, Spies M,  et al. (March 2017). "Administration of ketamine for unipolar and bipolar depression". International Journal of Psychiatry in Clinical Practice. 21 (1): 2–12. doi:10.1080/13651501.2016.1254802. PMID 28097909. S2CID 35626369.

^ Jump up to: a b Bartova L, Vogl SE, Stamenkovic M, Praschak-Rieder N, Naderi-Heiden A, Kasper S, Willeit M (November 2015). "Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases". European Neuropsychopharmacology. 25 (11): 2183–4. doi:10.1016/j.euroneuro.2015.07.021. PMID 26302763. S2CID 39039021.

^ Seeman P, Guan HC (November 2008). "Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia". Synapse. 62 (11): 819–28. doi:10.1002/syn.20561. PMID 18720422. S2CID 206519749.

^ Seeman P, Guan HC, Hirbec H (August 2009). "Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil". Synapse. 63 (8): 698–704. doi:10.1002/syn.20647. PMID 19391150. S2CID 17758902.

^ The Role of Brain Dopamine. Springer Science & Business Media. 6 December 2012. pp. 23–. ISBN 978-3-642-73897-5.

^ Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD,  et al. (March 1994). "Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses". Archives of General Psychiatry. 51 (3): 199–214. doi:10.1001/archpsyc.1994.03950030035004. PMID 8122957.

^ Hergovich N, Singer E, Agneter E, Eichler HG, Graselli U, Simhandl C, Jilma B (May 2001). "Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. a randomized, double-blind, placebo-controlled trial". Neuropsychopharmacology. 24 (5): 590–3. doi:10.1016/S0893-133X(00)00194-9. PMID 11282259.

^ Jump up to: a b Rabiner EA (May 2007). "Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?". Journal of Psychopharmacology. 21 (3): 253–8. doi:10.1177/0269881107077767. PMID 17591653. S2CID 23776189.

^ Jump up to: a b Idvall J, Ahlgren I, Aronsen KR, Stenberg P (December 1979). "Ketamine infusions: pharmacokinetics and clinical effects". Br J Anaesth. 51 (12): 1167–73. doi:10.1093/bja/51.12.1167. PMID 526385.

^ Domino EF, Zsigmond EK, Domino LE, Domino KE, Kothary SP, Domino SE (February 1982). "Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay". Anesth Analg. 61 (2): 87–92. doi:10.1213/00000539-198202000-00004. PMID 7198883. S2CID 27596215.

^ White PF, Schüttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ (February 1985). "Comparative pharmacology of the ketamine isomers. Studies in volunteers". Br J Anaesth. 57 (2): 197–203. doi:10.1093/bja/57.2.197. PMID 3970799.

^ Stenberg P, Idvall J (July 1981). "Does ketamine metabolite II exist in vivo?". Br J Anaesth. 53 (7): 778. doi:10.1093/bja/53.7.778. PMID 7248132.

^ Li Y, Jackson KA, Slon B, Hardy JR, Franco M, William L, Poon P, Coller JK, Hutchinson MR, Currow DC, Somogyi AA (August 2015). "CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects". Br J Clin Pharmacol. 80 (2): 276–84. doi:10.1111/bcp.12614. PMC 4541975. PMID 25702819.

^ Synthesis of ketamine references:
Stevens CL, Klundt IL, Munk ME, Pillai MD (1965). "Amino ketone rearrangements. IV. Thermal rearrangements of α-amino methyl ketones". Journal of Organic Chemistry. 30 (9): 2967–72. doi:10.1021/jo01020a019.
.mw-parser-output .citation{word-wrap:break-word}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}US patent 3254124, Stevens, Calvin L., "Aminoketones and methods for their production", issued 1966-05-31,  assigned to Parke Davis & Co. 
BE 634208, Stevens, Calvin L., "Procédé de production d'aminocétones", issued 1963-07-15. 

^ Krüger AD (1998). "[Current aspects of using ketamine in childhood]". Anaesthesiologie und Reanimation (in German). 23 (3): 64–71. PMID 9707751.

^ Chankvetadze B, Burjanadze N, Breitkreutz J, Bergander K, Bergenthal D, Kataeva O, Fröhlich R, Luftmann H, Blaschke G (2002). "Mechanistic study on the opposite migration order of the enantiomers of ketamine with α- and β-cyclodextrin in capillary electrophoresis". Journal of Separation Science. 25 (15–17): 1155–1166. doi:10.1002/1615-9314(20021101)25:15/17<1155::AID-JSSC1155>3.0.CO;2-M.

^ Feng N, Vollenweider FX, Minder EI, Rentsch K, Grampp T, Vonderschmitt DJ. Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther. Drug Monit. 17: 95–100, 1995.

^ Parkin MC, Turfus SC, Smith NW, Halket JM, Braithwaite RA, Elliott SP, Osselton MD, Cowan DA, Kicman AT. Detection of ketamine and its metabolites in urine by ultra high pressure liquid chromatography-tandem mass spectrometry. J. Chrom. B 876: 137–142, 2008.

^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 806–808.

^ Corssen G, Domino EF (January–February 1966). "Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581". Anesthesia and Analgesia. 45 (1): 29–40. doi:10.1213/00000539-196601000-00007. PMID 5325977. S2CID 29516392.

^ Jump up to: a b "Ketamine". Center for Substance Abuse Research (CESAR); University of Maryland, College Park. 29 October 2013. Archived from the original on 12 November 2013. Retrieved 27 July 2014.

^ Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (February 2000). "Antidepressant effects of ketamine in depressed patients". Biol Psychiatry. 47 (4): 351–4. doi:10.1016/s0006-3223(99)00230-9. PMID 10686270. S2CID 43438286.

^ Dhir A (January 2017). "Investigational drugs for treating major depressive disorder". Expert Opinion on Investigational Drugs. 26 (1): 9–24. doi:10.1080/13543784.2017.1267727. PMID 27960559. S2CID 45232796.

^ Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 584–585. ISBN 978-3-88763-075-1.

^ Poisons Standard October 2015 "Archived copy". Archived from the original on 19 January 2016. Retrieved 6 January 2016.{{cite web}}:  CS1 maint: archived copy as title (link)

^ Legal status of ketamine in Canada references:
"Statutes of Canada (S.C.) Controlled Drugs and Substances Act (S.C. 1996 c.19) Schedule I § 14". Justice Laws Website. Government of Canada. 12 June 2014. Archived from the original on 22 November 2013.
"Order Amending Schedule I to the Controlled Drugs and Substances Act" (PDF). Canada Gazette Part II. Vol. 139, no. 19. 21 September 2005. p. 2130. Archived from the original (PDF) on 8 August 2014. Retrieved 2 August 2014.
"Status of ketamine under CDSA". Canadian Society of Customs Brokers. 2 May 2005. Archived from the original on 10 August 2014. Retrieved 2 August 2014.

^ "Ketamine drug brought under 'Schedule X' to curb abuse". The Times of India. 7 January 2014. Archived from the original on 14 April 2014. Retrieved 2 August 2014.

^ Sumitra DR (30 December 2013). "Govt makes notorious 'date rape' drug ketamine harder to buy or sell". The Times of India. Archived from the original on 30 December 2013.

^ Baker N (12 February 2014), Response to ACMD recommendation on ketamine (PDF) (Correspondence to Les Iverson [chair of]; Advisory Council on the Misuse of Drugs), Crown copyright; Open Government Licence, archived (PDF) from the original on 28 February 2014, retrieved 21 February 2014.

^ Dixon H (12 February 2014). "Party drug ketamine to be upgraded to Class B". The Daily Telegraph. Archived from the original on 9 June 2014. Retrieved 2 August 2014.

^ Marshall DR (13 July 1999). "Schedules of Controlled Substances: Placement of Ketamine into Schedule III [21 CFR Part 1308. Final Rule 99-17803]" (PDF). Rules and Regulations. Federal Register. 64 (133): 37673–5. Archived (PDF) from the original on 5 May 2015.

^ Giannini AJ, Underwood NA, Condon M (November 2000). "Acute ketamine intoxication treated by haloperidol: a preliminary study". American Journal of Therapeutics. 7 (6): 389–91. doi:10.1097/00045391-200007060-00008. PMID 11304647.

^ Giannini AJ (1999). Drug Abuse. Los Angeles: Health Information Press. p. 104. ISBN 978-1-885987-11-2.

^ References for recreational use in literature:
Lilly JC (1997). The Scientist: A Metaphysical Autobiography. Berkeley, CA: Ronin. pp. 144–. ISBN 978-0-914171-72-0.
Kelly K (2001). The Little Book of Ketamine. Ronin. pp. 23, 40–45, 46–51, ibid. ISBN 978-1-57951-121-0.
Alltounian HS, Moore M (1978). Journeys Into the Bright World. Rockport, MA: Para Research. ISBN 978-0-914918-12-7.
Palmer C, Horowitz M (2000). Sisters of the Extreme: Women Writing on the Drug Experience. Inner Traditions. pp. 254–258, ibid. ISBN 978-0-89281-757-3.
Turner DM (1994). The Essential Psychedelic Guide. San Francisco: Panther Press. ISBN 978-0-9642636-1-1.

^ Jansen K (2001). Ketamine: Dreams and Realities. Multidisciplinary Association for Psychedelic Studies. pp. 50, 89. ISBN 978-0-9660019-3-8.

^ Woodard, D., “The Ketamine Necromance”, in A. Parfrey, Apocalypse Culture II (Los Angeles: Feral House, 2000), pp. 288–295.

^ Jump up to: a b See Max Daly, 2014, "The Sad Demise of Nancy Lee, One of Britain's Ketamine Casualties," at Vice (online), 23 July 2014, see "The Sad Demise of Nancy Lee, One of Britain's Ketamine Casualties". 23 July 2014. Archived from the original on 7 June 2015. Retrieved 7 June 2015., accessed 7 June 2015.

^ The Crown, 2013, "Drug related deaths involving ketamine in England and Wales," a report of the Mortality team, Life Events and Population Sources Division, Office for National Statistics, the Crown (U.K.), see "Archived copy". Archived from the original on 7 June 2015. Retrieved 7 June 2015.{{cite web}}:  CS1 maint: archived copy as title (link) and "Deaths Related to Drug Poisoning in England and Wales – Office for National Statistics". Archived from the original on 19 June 2015. Retrieved 7 June 2015., accessed 7 June 2015.

^ "Do you know... Ketamine". Knowledge Exchange. Toronto: Centre for Addiction and Mental Health. 2003. Archived from the original on 7 April 2014. Retrieved 27 July 2014.

^ Robertson SA, Taylor PM (October 2004). "Pain management in cats—past, present and future. Part 2. Treatment of pain—clinical pharmacology". Journal of Feline Medicine and Surgery. 6 (5): 321–33. doi:10.1016/j.jfms.2003.10.002. PMID 15363764. S2CID 25572412.

^ Lamont LA (November 2008). "Adjunctive analgesic therapy in veterinary medicine". The Veterinary Clinics of North America. Small Animal Practice. 38 (6): 1187–203, v. doi:10.1016/j.cvsm.2008.06.002. PMID 18954680.

^ Stunkard JA, Miller JC (September 1974). "An outline guide to general anesthesia in exotic species". Veterinary Medicine, Small Animal Clinician. 69 (9): 1181–6. PMID 4604091.

^ Riviere JE, Papich MG (2009). Veterinary Pharmacology and Therapeutics. John Wiley & Sons. p. 200. ISBN 978-1-118-68590-7.

^ Standard Operating Procedure No. 1 Anesthesia and Analgesia in Rodents, Washington College, 2012, pp. 1–2, archived from the original on 4 August 2013, retrieved 27 November 2015

^ Hubbell JA, Muir WW, Sams RA (November 1980). "Guaifenesin: cardiopulmonary effects and plasma concentrations in horses". American Journal of Veterinary Research. 41 (11): 1751–5. PMID 7212404.

^ Woodall AJ, McCrohan CR (December 2000). "Excitatory actions of propofol and ketamine in the snail Lymnaea stagnalis". Comparative Biochemistry and Physiology. Toxicology & Pharmacology. 127 (3): 297–305. doi:10.1016/S0742-8413(00)00155-9. PMID 11246501.


External links[edit]



Wikimedia Commons has media related to Ketamine.

"Ketamine". Drug Information Portal. U.S. National Library of Medicine.
"Ketamine hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
DEA: Ketamine Fact Sheet
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}showMedical uses
show.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteGeneral anesthetics (N01A)Inhalational
Chloroethane (ethyl chloride)‡
Chloroform‡
Cyclopropane‡
Desflurane
Diethyl ether‡
Enflurane
Ethylene‡
Fluroxene‡
Halothane#
Isoflurane#
Methoxyflurane
Methoxypropane‡
Nitrous oxide#
Sevoflurane
Trichloroethylene‡
Vinyl ether‡
Xenon
InjectionPhenols
Fospropofol
Propofol#
Barbiturates
Hexobarbital
Methohexital
Narcobarbital
Thiopental#
Thiotetrabarbital
Opioids
Morphine#
Oxycodone
Anileridine‡
Embutramide‡
Fentanyl#
Alfentanil
Phenoperidine
Remifentanil÷
Sufentanil
Arylcyclohexylamines
Esketamine
Ketamine#
Phencyclidine‡
Tiletamine
Neuroactive steroids
Alfadolone
Alfaxalone
Hydroxydione
Others
Etomidate
Propanidid‡

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

showvteAnalgesics (N02A, N02B)OpioidsOpiates/opium
Codeine#
+aspirin
+paracetamol
Morphine# (+naltrexone)
Opium
Laudanum
Paregoric
Semisynthetic
Acetyldihydrocodeine
Benzylmorphine
Buprenorphine (+naloxone)
Butorphanol
Desomorphine
Diamorphine (heroin)
Dihydrocodeine (+paracetamol)
Dihydromorphine
Etorphine
Ethylmorphine
Hydrocodone (+paracetamol, +ibuprofen, +aspirin)
Hydromorphinol
Hydromorphone
Levorphanol
Metopon
Nalbuphine
Nicocodeine
Nicodicodine
Nicomorphine
Oxycodone (+paracetamol, +aspirin, +ibuprofen, +naloxone, +naltrexone)
Oxymorphone
Papaveretum
Thebacon
Synthetic
Alfentanil
Alphaprodine
Anileridine
Bezitramide
Carfentanil
Dextromoramide
Dextropropoxyphene
Dezocine
Dimenoxadol
Dipipanone
Ethoheptazine
Fentanyl# (+fluanisone)
Ketobemidone
Lofentanil
Meptazinol
Methadone#
NFEPP
Norpipanone
Oliceridine
Pentazocine
Pethidine (meperidine)
Phenadoxone
Phenazocine
Phenoperidine
Piminodine
Piritramide
Proheptazine
Propiram
Remifentanil
Sufentanil
Tapentadol
Tilidine
Tramadol
Viminol
Paracetamol-type
Acetanilide‡
Bucetin‡
Butacetin‡
Paracetamol (acetaminophen)#
+aspirin/caffeine
+codeine
+hydrocodone
+metoclopramide
+oxycodone
+propyphenazone/caffeine
Parapropamol‡
Phenacetin‡
Propacetamol‡
NSAIDsPropionates
Benoxaprofen ‡
Fenoprofen
Flurbiprofen
Ibuprofen# (Dexibuprofen)
Ketoprofen (Dexketoprofen)
Loxoprofen
Naproxen
Oxaprozin
Suprofen
Tiaprofenic acid
Zaltoprofen
Oxicams
Isoxicam
Lornoxicam
Meloxicam
Piroxicam
Tenoxicam
Acetates
Acemetacin
Bromfenac
Diclofenac
Etodolac
Indometacin (Indometacin farnesil)
Ketorolac
Sulindac
Tolmetin
Zomepirac ‡
COX-2 inhibitors
Celecoxib (+tramadol)
Etoricoxib
Lumiracoxib ‡
Parecoxib
Rofecoxib ‡
Valdecoxib ‡
Fenamates
Flufenamic acid
Meclofenamic acid
Mefenamic acid
Tolfenamic acid
Salicylates
Aspirin (acetylsalicylic acid)# (+paracetamol/caffeine)
Aloxiprin
Benorylate
Carbasalate calcium
Choline salicylate
Diflunisal
Dipyrocetyl
Ethenzamide
Guacetisal
Imidazole salicylate
Magnesium salicylate
Morpholine salicylate
Potassium salicylate
Salicin
Salicylamide
Salsalate
Sodium salicylate
Wintergreen (methyl salicylate)
Pyrazolones
Aminophenazone‡
Ampyrone
Metamizole (dipyrone)
Nifenazone
Phenazone
Propyphenazone (+paracetamol/caffeine)
Others
Benzydamine
Floctafenine
Glafenine
Nabumetone
Nimesulide
Proquazone
Cannabinoids
Cannabidiol
Cannabis
Nabilone
Nabiximols
Tetrahydrocannabinol (dronabinol)
Ion channelmodulatorsCalcium blockers
Alcohol (ethanol)
Gabapentin
Gabapentin enacarbil
Leconotide
Mirogabalin
Pregabalin
Ziconotide
Sodium blockers
Carbamazepine
Lacosamide
Local anesthetics (e.g., cocaine, lidocaine)
Mexiletine
Nefopam
Tricyclic antidepressants (e.g., amitriptyline#)
Nav1.7/1.8-selective: DSP-2230§
Funapide§
PF-05089771§
Potassium openers
Flupirtine‡
Myorelaxants
Carisoprodol
Chlorzoxazone
Cyclobenzaprine
Mephenoxalone
Methocarbamol
Orphenadrine
Others
Analgecine
Analgesic adjuvant
Bedinvetmab
Camphor
Capsaicin
Clonidine
Frunevetmab
Ketamine
Menthol
Methoxyflurane
Phenazopyridine
Proglumide
Rimazolium
Tanezumab

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

showvteAntidepressants (N06A)hideSpecific reuptake inhibitors and/or receptor modulatorsSSRIs
Citalopram
Escitalopram
Fluoxetine#
Fluvoxamine
Indalpine‡
Paroxetine
Sertraline
Zimelidine‡
SNRIs
Desvenlafaxine
Duloxetine
Levomilnacipran
Milnacipran
Tofenacin
Venlafaxine
NRIs
Atomoxetine
Reboxetine
Viloxazine
NDRIs
Amineptine‡
Bupropion
Nomifensine‡
NaSSAs
Mianserin
Mirtazapine
Setiptiline
SARIs
Etoperidone
Nefazodone
Trazodone
SMS
Vilazodone
Vortioxetine
Others
Agomelatine
Amisulpride
Esketamine
Etryptamine‡
Indeloxazine
flupentixol
Ketamine§
Medifoxamine‡
Metryptamine‡
Oxaflozane‡
Pivagabine‡
Tandospirone
Teniloxazine
Tianeptine
hideTricyclic and tetracyclic antidepressantsTCAs
Amineptine‡
Amitriptyline#
Amitriptylinoxide
Butriptyline‡
Clomipramine#
Demexiptiline‡
Desipramine
Dibenzepin
Dimetacrine‡
Dosulepin
Doxepin
Imipramine
Imipraminoxide‡
Iprindole‡
Lofepramine
Melitracen
Metapramine‡
Nitroxazepine
Nortriptyline
Noxiptiline
Opipramol
Pipofezine
Propizepine‡
Protriptyline
Quinupramine‡
Tianeptine
Trimipramine
TeCAs
Amoxapine
Maprotiline
Mianserin
Mirtazapine
Setiptiline
Others
Tiazesim
hideMonoamine oxidase inhibitorsNon-selective
Irreversible: Benmoxin‡
Iproclozide‡
Iproniazid‡
Isocarboxazid
Isoniazid#
Linezolid#
Mebanazine‡
Nialamide‡
Octamoxin‡
Phenelzine
Pheniprazine‡
Phenoxypropazine‡
Pivhydrazine‡
Safrazine‡
Tedizolid
Tranylcypromine
Reversible: Caroxazone‡
Mixed: Bifemelane
MAOA-selective
Reversible: Eprobemide
Metralindole
Minaprine‡
Moclobemide
Pirlindole
Tetrindole
Toloxatone
MAOB-selective
Irreversible: Selegiline
hideAdjunctive therapies
Atypical antipsychotics (aripiprazole, brexpiprazole, lurasidone, olanzapine, quetiapine, risperidone)
Buspirone
Lithium (lithium carbonate, lithium citrate)
Thyroid hormones (triiodothyronine (T3), levothyroxine (T4))
hideMiscellaneous
Ademetionine (SAMe)
Hypericum perforatum (St. John's Wort)
Oxitriptan (5-HTP)
Rubidium chloride (RbCl)
Tryptophan

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

showRecreational uses
showvteRecreational drug useMajor recreational drugsDepressants
Barbiturates
Benzodiazepines
Carbamates
Ethanol (alcohol)
Alcoholic drinks
Beer
Wine
Gabapentinoids
GHB
Inhalants
Medical
Nitrous oxide (recreational use)
Hazardous solvents
contact adhesives
Gasoline
nail polish remover
Paint thinner
Other
Freon
Kava
Nonbenzodiazepines
Quinazolinones
Opioids
Buprenorphine
Suboxone
Subutex
Codeine
Desomorphine
Krokodil
Dextropropoxyphene
Darvocet
Darvon
Fentanyl
Diamorphine
Heroin
Hydrocodone
Hydromorphone
Dilaudid
Methadone
Mitragyna speciosa
Kratom
Morphine
Opium
Oxycodone
/paracetamol
Tramadol
Stimulants
Amphetamine
Arecoline
Areca
Betel
Caffeine
Coffee
Energy drinks
Tea
Cathinone
Khat
Cocaine
Coca
Crack
Ephedrine
Ephedra
MDPV
Mephedrone
Methamphetamine
Methylone
Methylphenidate
Modafinil
Nicotine
Tobacco
Theobromine
Cocoa
Chocolate
Entactogens
2C series
6-APB
Benzofury
AMT
MDA
MDMA
Ecstasy
HallucinogensPsychedelics
Bufotenin
Psychoactive toads
Vilca
Yopo
DMT
Ayahuasca
LSA
LSD-25
Mescaline
Peruvian torch
Peyote
San Pedro
Psilocybin / Psilocin
Psilocybin mushrooms
Dissociatives
DXM (recreational use)
Glaucine
Inhalants
Nitrous oxide (recreational use)
alkyl nitrites
poppers
amyl nitrite
Ketamine
MXE
Muscimol
Amanita muscaria
PCP
Salvinorin A
Salvia divinorum
Deliriants
Atropine and Scopolamine
Atropa belladonna
Datura
Hyoscyamus niger
Mandragora officinarum
Dimenhydrinate
Diphenhydramine
Cannabinoids
THC
Cannabis (Marijuana)
Hashish
Hash oil
Neocannabinoid / synthetic cannabinoids
JWH-018
APICA
APINACA
Spice
Oneirogens
Calea zacatechichi
Silene capensis
Club drugs
Cocaine
Quaaludes
MDMA (Ecstasy)
Nitrous oxide (recreational use)
Poppers
Drug cultureCannabis culture
420
Cannabis cultivation
Cannabis rights leaders
Cannabis smoking
Cannabis Social Club
Head shop
Legal history of cannabis in the United States
Legality of cannabis
Marijuana Policy Project
Medical cannabis
NORML
Cannabis and religion
Stoner film
Coffee culture
Coffee break
Coffeehouse
Latte art
Teahouse
Drinking culture
Bartending
Beer culture
Beer festival
Binge drinking
Diethyl ether
Drinking games
Drinking song
Happy hour
Hip flask
Nightclub
Pub
Pub crawl
Sommelier
Sports bar
Tailgate party
Wine bar
Wine tasting
Psychedelia
Psychonautics
Art
Drug
Era
Experience
Literature
Music
Microdosing
Therapy
Smoking culture
Cigarette card
Fashion cigarettes
Cloud-chasing
Loosie
Smokeasy
Smoking fetishism
Tobacco smoking
Other
Club drug
Counterculture of the 1960s
Dance party
Drug paraphernalia
Drug tourism
Entheogen
Hippie
Needle sharing
Nootropic
Party and play
Poly drug use
Rave
Religion and drugs
Self-medication
Sex and drugs
Whoonga
Drug production and tradeDrug production
Coca production in Colombia
Drug precursors
Opium production in Afghanistan
Rolling meth lab
Drug trade
Illegal drug trade
Colombia
Darknet market
Pharmaceutical distribution
Beer shop
Cannabis shop
Liquor store
Liquor license
Issues with drug use
Abuse
Addiction
Date rape drug
Dependence
Opioid replacement therapy
Prevention
Rehabilitation
Responsible use
Driving impaired
Drug checking
Reagent testing
Drug harmfulness
Effects of cannabis
Drug-related crime
Fetal alcohol spectrum disorder
Long-term effects of cannabis
Neurotoxicity
Overdose
Passive smoking
of tobacco or other substances
Legality of drug useInternational
International Drug Control Conventions
1961 Narcotic Drugs
1971 Psychotropic Substances
1988 Drug Trafficking
Other treaties addressing drugs
Law of the Sea Convention
Convention Against Doping
Council of the European Union decisions on designer drugs
State level
Drug policy
Decriminalization
Prohibition
Supply reduction
Policy reform
Demand reduction
Drug Policy Alliance
Harm reduction
Law Enforcement Action Partnership
Liberalization
Latin America
Students for Sensible Drug Policy
Transform Drug Policy Foundation
Drug policyby country
Australia
Canada
Germany
India
Netherlands
Portugal
Slovakia
Soviet Union
Sweden
Switzerland
United States
Just Say No
Office of National Drug Control Policy
School district drug policies
California
Colorado
Maryland
Virginia
Other
Arguments for and against drug prohibition
Capital punishment for drug trafficking
Cognitive liberty
Designer drug
Drug court
Drug possession
Drug test
Narc
Politics of drug abuse
War on drugs
Mexican drug war
Plan Colombia
Philippine drug war
Zero tolerance
Lists of countries by...
Alcohol legality
Alcohol consumption
Anabolic steroid legality
Cannabis legality
Annual use
Lifetime use
Tobacco consumption
Cocaine legality
Cocaine use
Methamphetamine legality
Opiates use
Psilocybin mushrooms legality
Salvia legality

showvteHallucinogensPsychedelics(5-HT2Aagonists)Benzofurans
2C-B-FLY
2CBFly-NBOMe
5-MeO-BFE
5-MeO-DiBF
Bromo-DragonFLY
F-2
F-22
TFMFly
Lyserg‐amides
1B-LSD
1cP-LSD
1P-ETH-LAD
1P-LSD
1cP-AL-LAD
1cP-MiPLA
1V-LSD
2-Butyllysergamide
3-Pentyllysergamide
AL-LAD
ALD-52
BU-LAD
Diallyllysergamide
Dimethyllysergamide
ECPLA
Ergometrine
ETH-LAD
IP-LAD
LAE-32
LAMPA
LPD-824
LSA
LSD
LSD-Pip
LSH
LSM-775
LSZ
Methylergometrine
MIPLA
Methysergide
MLD-41
PARGY-LAD
PRO-LAD
Phenethyl‐amines2C-x
2C-B
2C-B-AN
2C-Bn
2C-Bu
2C-C
2C-CN
2C-CP
2C-D
2C-E
2C-EF
2C-F
2C-G
2C-G-1
2C-G-2
2C-G-3
2C-G-4
2C-G-5
2C-G-6
2C-G-N
2C-H
2C-I
2C-iP
2C-N
2C-NH2
2C-O
2C-O-4
2C-P
2C-Ph
2C-SE
2C-T
2C-T-2
2C-T-3
2C-T-4
2C-T-5
2C-T-6
2C-T-7
2C-T-8
2C-T-9
2C-T-10
2C-T-11
2C-T-12
2C-T-13
2C-T-14
2C-T-15
2C-T-16
2C-T-17
2C-T-18
2C-T-19
2C-T-20
2C-T-21
2C-T-22
2C-T-22.5
2C-T-23
2C-T-24
2C-T-25
2C-T-27
2C-T-28
2C-T-30
2C-T-31
2C-T-32
2C-T-33
2C-TFE
2C-TFM
2C-YN
2C-V
    25x-NBx25x-NB
25B-NB
25C-NB
25x-NB3OMe
25B-NB3OMe
25C-NB3OMe
25D-NB3OMe
25E-NB3OMe
25H-NB3OMe
25I-NB3OMe
25N-NB3OMe
25P-NB3OMe
25T2-NB3OMe
25T4-NB3OMe
25T7-NB3OMe
25TFM-NB3OMe
25x-NB4OMe
25B-NB4OMe
25C-NB4OMe
25D-NB4OMe
25E-NB4OMe
25H-NB4OMe
25I-NB4OMe
25N-NB4OMe
25P-NB4OMe
25T2-NB4OMe
25T4-NB4OMe
25T7-NB4OMe
25TFM-NB4OMe
25x-NBF
25B-NBF
25C-NBF
25D-NBF
25E-NBF
25H-NBF
25I-NBF
25P-NBF
25T2-NBF
25T7-NBF
25TFM-NBF
25x-NBMD
25B-NBMD
25C-NBMD
25D-NBMD
25E-NBMD
25F-NBMD
25H-NBMD
25I-NBMD
25P-NBMD
25T2-NBMD
25T7-NBMD
25TFM-NBMD
25x-NBOH
25B-NBOH
25C-NBOH
25CN-NBOH
25D-NBOH
25E-NBOH
25F-NBOH
25H-NBOH
25I-NBOH
25P-NBOH
25T2-NBOH
25T7-NBOH
25TFM-NBOH
25x-NBOMe
25B-NBOMe
25C-NBOMe
25CN-NBOMe
25D-NBOMe
25E-NBOMe
25F-NBOMe
25G-NBOMe
25H-NBOMe
25I-NBOMe
25iP-NBOMe
25N-NBOMe
25P-NBOMe
25T-NBOMe
25T2-NBOMe
25T4-NBOMe
25T7-NBOMe
25TFM-NBOMe
Atypical structures
25B-N1POMe
25B-NAcPip
25B-NB23DM
25B-NB25DM
25C-NBCl
25C-NBOEt
25C-NBOiPr
25I-N2Nap1OH
25I-N3MT2M
25I-N4MT3M
25I-NB34MD
25I-NBAm
25I-NBBr
25I-NBMeOH
25I-NBTFM
2CBCB-NBOMe
2CBFly-NBOMe
4-EA-NBOMe
5-APB-NBOMe
5MT-NBOMe
C30-NBOMe
DOB-NBOMe
DOI-NBOMe
FECIMBI-36
MDPEA-NBOMe
NBOMe-escaline
NBOMe-mescaline
ZDCM-04
25x-NMx
25B-NMe7BF
25B-NMe7BT
25B-NMe7Box
25B-NMe7DHBF
25B-NMe7Ind
25B-NMe7Indz
25B-NMePyr
25I-NMe7DHBF
25I-NMeFur
25I-NMeTHF
25I-NMeTh

3C-x
3C-AL
3C-BZ
3C-DFE
3C-E
3C-MAL
3C-P
4C-x
4C-B
4C-C
4C-D
4C-E
4C-I
4C-N
4C-P
4C-T-2
DOx
DOT
DOB
DOC
DOEF
DOET
DOF
DOI
DOiPR
DOM
DON
DOPR
DOTFM
MEM
HOT-x
HOT-2
HOT-7
HOT-17
MDxx
DMMDA
DMMDA-2
Lophophine
MDA
MDAI
MDBZ
MDMA
MMDA
MMDA-2
MMDA-3a
MMDMA
Mescaline (subst.)
2-Bromomescaline
3-TE
4-TE
3-TM
4-TM
Allylescaline
Asymbescaline
Buscaline
Cyclopropylmescaline
Difluoromescaline
Difluoroescaline
Escaline
Fluoroproscaline
Isobuscaline
Isoproscaline
Jimscaline
Mescaline
Metaescaline
Methallylescaline
Proscaline
Thioproscaline
Trifluoroescaline
Trifluoromescaline
TMAs
TMA
TMA-2
TMA-3
TMA-4
TMA-5
TMA-6
Others
2C-B-BUTTERFLY
2C-B-DragonFLY
2C-B-DragonFLY-NBOH
2C-B-FLY-NB2EtO5Cl
2CB-5-hemifly
2CB-Ind
2CD-5EtO
2-TOET
5-TOET
2-TOM
5-TOM
BOB
BOD
βk-2C-B
βk-2C-I
DESOXY
DMCPA
DMBMPP
DOB-FLY
Fenfluramine
Ganesha
Macromerine
MMA
TCB-2
TOMSO
Piperazines
2C-B-PP
BZP
pFPP
Tryptaminesalpha-alkyltryptamines
4,5-DHP-α-MT
5-MeO-α-ET
5-MeO-α-MT
α-ET
α-MT
x-DALT
(Daltocin) 4-HO-DALT
(Daltacetin) 4-AcO-DALT
5-MeO-DALT
DALT
x-DET
(Ethacetin) 4-AcO-DET
(Ethocin) 4-HO-DET
5-MeO-DET
(T-9) DET
(Ethocybin) 4-PO-DET
x-DiPT
(Ipracetin) 4-AcO-DiPT
(Iprocin) 4-HO-DiPT
5-MeO-DiPT
DiPT
x-DMT
4,5-DHP-DMT
2,N,N-TMT
4-AcO-DMT
4-HO-5-MeO-DMT
4,N,N-TMT
4-Propionyloxy-DMT
5,6-diBr-DMT
5-AcO-DMT
5-Bromo-DMT
5-MeO-2,N,N-TMT
5-MeO-4,N,N-TMT
5-MeO-α,N,N-TMT
5-MeO-DMT
5-N,N-TMT
7,N,N-TMT
α,N,N-TMT
(Bufotenin) 5-HO-DMT
DMT
Norbaeocystin
(Psilocin) 4-HO-DMT
(Psilocybin) 4-PO-DMT
x-DPT
(Depracetin) 4-AcO-DPT
(Deprocin) 4-HO-DPT
5-MeO-DPT
(The Light) DPT
Ibogaine-related
18-MAC
18-MC
Coronaridine
Ibogaine
Ibogamine
ME-18-MC
Noribogaine
Tabernanthine
Voacangine
x-MET
(Metocin) 4-HO-MET
(Metocetin) 4-AcO-MET
5-MeO-MET
MET
x-MiPT
(Mipracetin) 4-AcO-MiPT
(Miprocin) 4-HO-MiPT
5-Me-MiPT
(Moxy) 5-MeO-MiPT
MiPT
Others
4-HO-DBT
4-HO-EPT
4-HO-McPT
(Lucigenol) 4-HO-MPMI
(Meprocin) 4-HO-MPT
5-MeO-EiPT
5-MeO-MALT
5-MeO-MPMI
Aeruginascin
Baeocystin
DBT
DCPT
EiPT
EPT
MPT
PiPT
Others
AL-38022A
ALPHA
Dimemebfe
Efavirenz
Glaucine
Lorcaserin
M-ALPHA
RH-34Also empathogens in general (e. g.: 5-APB, 5-MAPB, 6-APB and other substituted benzofurans).
Dissociatives(NMDARantagonists)Arylcyclo‐hexylaminesKetamine-related
2-Fluorodeschloroketamine
Arketamine ((R)-ketamine)
Deschloroketamine
Ethketamine (N-Ethylnorketamine)
Esketamine ((S)-ketamine)
Ketamine
Methoxetamine
Methoxmetamine
Methoxyketamine
MXiPr
Norketamine
Tiletamine
PCP-related
2'-Oxo-PCE
3-HO-PCP
3-MeO-PCE
3-MeO-PCMo
3-MeO-PCP
4-MeO-PCP
BDPC
Dieticyclidine (PCDE)
Eticyclidine (PCE)
PCPr
Phencyclidine (PCP)
Rolicyclidine (PCPy)
Tenocyclidine (TCP)
Others
BTCP
Gacyclidine
PRE-084
Diarylethylamines
Diphenidine
Ephenidine
Fluorolintane
Methoxphenidine
Morphinans
Dextrallorphan
Dextromethorphan
Dextrorphan
Racemethorphan
Racemorphan
Others
2-EMSB
2-MDP
8A-PDHQ
Aptiganel
Budipine
Delucemine
Dexoxadrol
Dizocilpine
Etoxadrol
Herkinorin
Ibogaine
Midafotel
NEFA
Neramexane
Nitrous oxide
Noribogaine
Perzinfotel
RB-64
Remacemide
Selfotel
Xenon
Deliriants(mAChRantagonists)
Atropine
Benactyzine
Benzatropine
Benzydamine
Biperiden
BRN-1484501
Brompheniramine
BZ
CAR-226,086
CAR-301,060
CAR-302,196
CAR-302,282
CAR-302,368
CAR-302,537
CAR-302,668
Chloropyramine
Chlorphenamine
Clemastine
CS-27349
Cyclizine
Cyproheptadine
Dicycloverine
Dimenhydrinate
Diphenhydramine
Ditran
Doxylamine
EA-3167
EA-3443
EA-3580
EA-3834
Elemicin
Flavoxate
Hyoscyamine
JB-318
JB-336
Meclozine
Mepyramine
Myristicin
Orphenadrine
Oxybutynin
Pheniramine
Phenyltoloxamine
Procyclidine
Promethazine
Scopolamine
Tolterodine
Trihexyphenidyl
Tripelennamine
Triprolidine
WIN-2299
OthersCannabinoids(CB1 agonists)Natural
Salvinorin A
THC (Dronabinol)
THCV
SyntheticAM-x
AM-087
AM-251
AM-279
AM-281
AM-356
AM-374
AM-381
AM-404
AM-411
AM-630
AM-661
AM-678
AM-679
AM-694
AM-735
AM-855
AM-881
AM-883
AM-905
AM-906
AM-919
AM-926
AM-938
AM-1116
AM-1172
AM-1220
AM-1221
AM-1235
AM-1241
AM-1248
AM-1710
AM-1714
AM-1902
AM-2201
AM-2212
AM-2213
AM-2232
AM-2233
AM-2389
AM-3102
AM-4030
AM-4054
AM-4056
AM-4113
AM-6545
CP x
CP 47,497
CP 55,244
CP 55,940
(±)-CP 55,940
(+)-CP 55,940
(-)-CP 55,940
HU-x
HU-210
HU-211
HU-239
HU-243
HU-308
HU-320
HU-331
HU-336
HU-345
JWH-x
JWH-007
JWH-015
JWH-018
JWH-019
JWH-030
JWH-047
JWH-048
JWH-051
JWH-057
JWH-073
JWH-081
JWH-098
JWH-116
JWH-120
JWH-122
JWH-133
JWH-139
JWH-147
JWH-148
JWH-149
JWH-149
JWH-161
JWH-164
JWH-166
JWH-167
JWH-171
JWH-175
JWH-176
JWH-181
JWH-182
JWH-184
JWH-185
JWH-192
JWH-193
JWH-194
JWH-195
JWH-196
JWH-197
JWH-198
JWH-199
JWH-200
JWH-203
JWH-205
JWH-210
JWH-210
JWH-213
JWH-220
JWH-229
JWH-234
JWH-249
JWH-250
JWH-251
JWH-253
JWH-258
JWH-300
JWH-302
JWH-307
JWH-336
JWH-350
JWH-359
JWH-387
JWH-398
JWH-424
Misc. designer cannabinoids
4-HTMPIPO
5F-AB-FUPPYCA
5F-AB-PINACA
5F-ADB
5F-ADB-PINACA
5F-ADBICA
5F-AMB
5F-APINACA
5F-CUMYL-PINACA
5F-NNE1
5F-PB-22
5F-SDB-006
A-796,260
A-836,339
AB-001
AB-005
AB-CHFUPYCA
AB-CHMINACA
AB-FUBINACA
AB-PINACA
ADAMANTYL-THPINACA
ADB-CHMINACA
ADB-FUBINACA
ADB-PINACA
ADBICA
ADSB-FUB-187
AMB-FUBINACA
APICA
APINACA
APP-FUBINACA
CB-13
CUMYL-PICA
CUMYL-PINACA
CUMYL-THPINACA
DMHP
EAM-2201
FAB-144
FDU-PB-22
FUB-144
FUB-APINACA
FUB-JWH-018
FUB-PB-22
FUBIMINA
JTE 7-31
JTE-907
Levonantradol
MDMB-CHMICA
MDMB-CHMINACA
MDMB-FUBINACA
MEPIRAPIM
MAM-2201
MDA-19
MN-18
MN-25
NESS-0327
NESS-040C5
Nabilone
Nabitan
NM-2201
NNE1
Org 28611
Parahexyl
PTI-1
PTI-2
PX-1
PX-2
PX-3
QUCHIC
QUPIC
RCS-4
RCS-8
SDB-005
SDB-006
STS-135
THC-O-acetate
THC-O-phosphate
THJ-018
THJ-2201
UR-144
WIN 55,212-2
XLR-11
D2 agonists
Apomorphine
Aporphine
Bromocriptine
Cabergoline
Lisuride
LSD
Memantine
Nuciferine
Pergolide
Phenethylamine
Piribedil
Pramipexole
Ropinirole
Rotigotine
Salvinorin AAlso indirect D2 agonists, such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, methamphetamine), and precursors (levodopa).
GABAAenhancers
CI-966
Eszopiclone
Ibotenic acid
Muscimol (Amanita muscaria)
Zaleplon
Zolpidem
Zopiclone
Inhalants(Mixed MOA)
Aliphatic hydrocarbons
Butane
Gasoline
Kerosene
Propane
Aromatic hydrocarbons
Toluene
Ethers
Diethyl ether
Enflurane
Haloalkanes
Chlorofluorocarbons
Chloroform
κOR agonists
2-EMSB
Alazocine
Bremazocine
Butorphan
Butorphanol
Cyclazocine
Cyclorphan
Cyprenorphine
Diprenorphine
Enadoline
Herkinorin
Heroin
HZ-2
Ibogaine
Ketazocine
Levallorphan
Levomethorphan
Levorphanol
LPK-26
Metazocine
Morphine
Nalbuphine
Nalmefene
Nalorphine
Noribogaine
Oxilorphan
Pentazocine
Phenazocine
Proxorphan
Racemethorphan
Racemorphan
Salvinorin A
Spiradoline
Tifluadom
U-50488
U-69,593
Xorphanol
Oneirogens
Calea zacatechichi
Silene capensis
Galantamine
Others
Glaucine
Isoaminile
Noscapine
Pukateine

showvteDrugs which induce euphoria
μ-Opioid receptor agonists (opioids) (e.g., morphine, heroin, hydrocodone, oxycodone, opium, kratom)
α2δ subunit-containing voltage-dependent calcium channels blockers (gabapentinoids) (e.g., gabapentin, pregabalin, phenibut)
AMPA receptor antagonists (e.g., perampanel)
CB1 receptor agonists (cannabinoids) (e.g., THC, cannabis)
Dopamine receptor agonists (e.g., levodopa)
Dopamine releasing agents (e.g., amphetamine, methamphetamine, MDMA, mephedrone)
Dopamine reuptake inhibitors (e.g., cocaine, methylphenidate)
GABAA receptor positive allosteric modulators (e.g., barbiturates, benzodiazepines, carbamates, ethanol (alcohol) (alcoholic drink), inhalants, nonbenzodiazepines, quinazolinones)
GHB (sodium oxybate) and analogues
Glucocorticoids (corticosteroids) (e.g., dexamethasone, prednisone)
nACh receptor agonists (e.g., nicotine, tobacco, arecoline, areca nut)
Nitric oxide prodrugs (e.g., alkyl nitrites (poppers))
NMDA receptor antagonists (e.g., DXM, ketamine, methoxetamine, nitrous oxide, phencyclidine, inhalants)
Orexin receptor antagonists (e.g., suvorexant)
See also: Recreational drug use
showPharmacodynamics
showAcetylcholine receptor modulators
showvteMuscarinic acetylcholine receptor modulatorsmAChRsAgonists
77-LH-28-1
AC-42
AC-260,584
Aceclidine
Acetylcholine
AF30
AF150(S)
AF267B
Alvameline
AQRA-741
Arecoline
Bethanechol
Bevonium
Butyrylcholine
Carbachol
CDD-0034
CDD-0078
CDD-0097
CDD-0098
CDD-0102
Cevimeline
Choline
cis-Dioxolane
Clozapine
Desmethylclozapine (norclozapine)
Ethoxysebacylcholine
Itameline
LY-593,039
L-689,660
LY-2,033,298
McNA343
Methacholine
Milameline
Muscarine
NGX-267
Ocvimeline
Oxotremorine
PD-151,832
Pilocarpine
RS86
Sabcomeline
SDZ 210-086
Sebacylcholine
Suberyldicholine
Talsaclidine
Tazomeline
Thiopilocarpine
Vedaclidine
VU-0029767
VU-0090157
VU-0152099
VU-0152100
VU-0238429
WAY-132,983
Xanomeline
YM-796
Antagonists
3-Quinuclidinyl benzilate
4-DAMP
Aclidinium bromide (+formoterol)
Abediterol
AF-DX 250
AF-DX 384
Ambutonium bromide
Anisodamine
Anisodine
Antihistamines (first-generation) (e.g., brompheniramine, buclizine, captodiame, chlorphenamine (chlorpheniramine), cinnarizine, clemastine, cyproheptadine, dimenhydrinate, dimetindene, diphenhydramine, doxylamine, meclizine, mequitazine, perlapine, phenindamine, pheniramine, phenyltoloxamine, promethazine, propiomazine, triprolidine)
AQ-RA 741
Atropine
Atropine methonitrate
Atypical antipsychotics (e.g., clozapine, fluperlapine, olanzapine (+fluoxetine), rilapine, quetiapine, tenilapine, zotepine)
Benactyzine
Benzatropine (benztropine)
Benzilone
Benzilylcholine mustard
Benzydamine
BIBN 99
Biperiden
Bornaprine
Camylofin
CAR-226,086
CAR-301,060
CAR-302,196
CAR-302,282
CAR-302,368
CAR-302,537
CAR-302,668
Caramiphen
Cimetropium bromide
Clidinium bromide
Cloperastine
CS-27349
Cyclobenzaprine
Cyclopentolate
Darifenacin
DAU-5884
Desfesoterodine
Dexetimide
DIBD
Dicycloverine (dicyclomine)
Dihexyverine
Difemerine
Diphemanil metilsulfate
Ditran
Drofenine
EA-3167
EA-3443
EA-3580
EA-3834
Emepronium bromide
Etanautine
Etybenzatropine (ethybenztropine)
Fenpiverinium
Fentonium bromide
Fesoterodine
Flavoxate
Glycopyrronium bromide (+beclometasone/formoterol, +indacaterol)
Hexahydrodifenidol
Hexahydrosiladifenidol
Hexbutinol
Hexocyclium
Himbacine
HL-031,120
Homatropine
Imidafenacin
Ipratropium bromide (+salbutamol)
Isopropamide
J-104,129
Hyoscyamine
Mamba toxin 3
Mamba toxin 7
Mazaticol
Mebeverine
Meladrazine
Mepenzolate
Methantheline
Methoctramine
Methylatropine
Methylhomatropine
Methylscopolamine
Metixene
Muscarinic toxin 7
N-Ethyl-3-piperidyl benzilate
N-Methyl-3-piperidyl benzilate
Nefopam
Octatropine methylbromide (anisotropine methylbromide)
Orphenadrine
Otenzepad (AF-DX 116)
Otilonium bromide
Oxapium iodide
Oxitropium bromide
Oxybutynin
Oxyphencyclimine
Oxyphenonium bromide
PBID
PD-102,807
PD-0298029
Penthienate
Pethidine
pFHHSiD
Phenglutarimide
Phenyltoloxamine
Pipenzolate bromide
Piperidolate
Pirenzepine
Piroheptine
Pizotifen
Poldine
Pridinol
Prifinium bromide
Procyclidine
Profenamine (ethopropazine)
Propantheline bromide
Propiverine
Quinidine
3-Quinuclidinyl thiochromane-4-carboxylate
Revefenacin
Rociverine
RU-47,213
SCH-57,790
SCH-72,788
SCH-217,443
Scopolamine (hyoscine)
Scopolamine butylbromide (hyoscine butylbromide)
Silahexacyclium
Sofpironium bromide
Solifenacin
SSRIs (e.g., femoxetine, paroxetine)
Telenzepine
Terodiline
Tetracyclic antidepressants (e.g., amoxapine, maprotiline, mianserin, mirtazapine)
Tiemonium iodide
Timepidium bromide
Tiotropium bromide
Tiquizium bromide
Tofenacin
Tolterodine
Tricyclic antidepressants (e.g., amitriptyline (+perphenazine), amitriptylinoxide, butriptyline, cidoxepin, clomipramine, desipramine, desmethyldesipramine, dibenzepin, dosulepin (dothiepin), doxepin, imipramine, lofepramine, nitroxazepine, northiaden (desmethyldosulepin), nortriptyline, protriptyline, quinupramine, trimipramine)
Tridihexethyl
Trihexyphenidyl
Trimebutine
Tripitamine (tripitramine)
Tropacine
Tropatepine
Tropicamide
Trospium chloride
Typical antipsychotics (e.g., chlorpromazine, chlorprothixene, cyamemazine (cyamepromazine), loxapine, mesoridazine, thioridazine)
Umeclidinium bromide (+vilanterol)
WIN-2299
Xanomeline
Zamifenacin
Precursors(and prodrugs)
Acetyl-coA
Adafenoxate
Choline (lecithin)
Citicoline
Cyprodenate
Dimethylethanolamine
Glycerophosphocholine
Meclofenoxate (centrophenoxine)
Phosphatidylcholine
Phosphatidylethanolamine
Phosphorylcholine
Pirisudanol
See also: Receptor/signaling modulators • Nicotinic acetylcholine receptor modulators • Acetylcholine metabolism/transport modulators
showvteNicotinic acetylcholine receptor modulatorsnAChRsAgonists(and PAMs)
5-HIAA
6-Chloronicotine
A-84,543
A-366,833
A-582,941
A-867,744
ABT-202
ABT-418
ABT-560
ABT-894
Acetylcholine
Altinicline
Anabasine
Anatabine
Anatoxin-a
AR-R17779
Bephenium hydroxynaphthoate
Butinoline
Butyrylcholine
Carbachol
Choline
Cotinine
Cytisine
Decamethonium
Desformylflustrabromine
Dianicline
Dimethylphenylpiperazinium
Epibatidine
Epiboxidine
Ethanol (alcohol)
Ethoxysebacylcholine
EVP-4473
EVP-6124
Galantamine
GTS-21
Ispronicline
Ivermectin
JNJ-39393406
Levamisole
Lobeline
MEM-63,908 (RG-3487)
Morantel
Nicotine (tobacco)
NS-1738
PHA-543,613
PHA-709,829
PNU-120,596
PNU-282,987
Pozanicline
Pyrantel
Rivanicline
RJR-2429
Sazetidine A
SB-206553
Sebacylcholine
SIB-1508Y
SIB-1553A
SSR-180,711
Suberyldicholine
Suxamethonium (succinylcholine)
Suxethonium (succinyldicholine)
TC-1698
TC-1734
TC-1827
TC-2216
TC-5214
TC-5619
TC-6683
Tebanicline
Tribendimidine
Tropisetron
UB-165
Varenicline
WAY-317,538
XY-4083
Antagonists(and NAMs)
18-MAC
18-MC
α-Neurotoxins (e.g., α-bungarotoxin, α-cobratoxin, α-conotoxin, many others)
ABT-126
Alcuronium
Allopregnanolone
Amantadine
Anatruxonium
AQW051
Atracurium
Barbiturates (e.g., pentobarbital, sodium thiopental)
BNC-210
Bungarotoxins (e.g., α-bungarotoxin, κ-bungarotoxin)
Bupropion
BW284C51
BW-A444
Candocuronium iodide (chandonium iodide)
Chlorisondamine
Cisatracurium
Coclaurine
Coronaridine
Curare
Cyclopropane
Dacuronium bromide
Decamethonium
Dehydronorketamine
Desflurane
Dextromethorphan
Dextropropoxyphene
Dextrorphan
Diadonium
DHβE
Dihydrochandonium
Dimethyltubocurarine (metocurine)
Dioscorine
Dipyrandium
Dizocilpine (MK-801)
Doxacurium
Encenicline
Enflurane
Erythravine
Esketamine
Fazadinium
Gallamine
Gantacurium chloride
Halothane
Hexafluronium
Hexamethonium (benzohexonium)
Hydroxybupropion
Hydroxynorketamine
Ibogaine
Isoflurane
Ketamine
Kynurenic acid
Laudanosine
Laudexium (laudolissin)
Levacetylmethadol
Levomethadone
Malouetine
ME-18-MC
Mecamylamine
Memantine
Methadone
Methorphan (racemethorphan)
Methyllycaconitine
Metocurine
Mivacurium
Morphanol (racemorphan)
Neramexane
Nitrous oxide
Norketamine
Pancuronium bromide
Pempidine
Pentamine
Pentolinium
Phencyclidine
Pipecuronium bromide
Progesterone
Promegestone
Radafaxine
Rapacuronium bromide
Reboxetine
Rocuronium bromide
Sevoflurane
Stercuronium iodide
Surugatoxin
Thiocolchicoside
Toxiferine
Tramadol
Trimetaphan camsilate (trimethaphan camsylate)
Tropeinium
Tubocurarine
Vanoxerine
Vecuronium bromide
Xenon
Precursors(and prodrugs)
Acetyl-coA
Adafenoxate
Choline (lecithin)
Citicoline
Cyprodenate
Dimethylethanolamine
Glycerophosphocholine
Meclofenoxate (centrophenoxine)
Phosphatidylcholine
Phosphatidylethanolamine
Phosphorylcholine
Pirisudanol
See also: Receptor/signaling modulators • Muscarinic acetylcholine receptor modulators • Acetylcholine metabolism/transport modulators
showvteDopamine receptor modulatorsD1-likeAgonists
Benzazepines: 6-Br-APB
Fenoldopam
SKF-38,393
SKF-77,434
SKF-81,297
SKF-82,958
SKF-83,959
Trepipam
Zelandopam
Ergolines: Cabergoline
CY-208,243
Dihydroergocryptine
LEK-8829
Lisuride
Pergolide
Terguride
Dihydrexidine derivatives: A-77636
A-86929
Adrogolide (ABT-431, DAS-431)
Dihydrexidine
Dinapsoline
Dinoxyline
Doxanthrine
Phenethylamines: BCO-001
Deoxyepinephrine (N-methyldopamine, epinine)
Dopexamine
Etilevodopa
Ibopamine
L-DOPA (levodopa)
Melevodopa
L-Phenylalanine
L-Tyrosine
XP21279
Others: A-68930
Apomorphine
Isocorypalmine
Nuciferine
PF-6649751
PF 6669571
Propylnorapomorphine
Rotigotine
SKF-89,145
SKF-89,626
Stepholidine
Tavapadon
Tetrahydropalmatine
PAMs
DETQ
DPTQ
Mevidalen (LY3154207)
Antagonists
Typical antipsychotics: Butaclamol
Chlorpromazine
Chlorprothixene
Flupentixol (flupenthixol) (+melitracen)
Fluphenazine
Loxapine
Perphenazine (+amitriptyline)
Pifluthixol
Thioridazine
Thiothixene
Trifluoperazine (+tranylcypromine)
Zuclopenthixol
Atypical antipsychotics: Asenapine
Clorotepine
Clotiapine
Clozapine
DHA-clozapine
Fluperlapine
Iloperidone
Norclozapine
Norquetiapine
Olanzapine (+fluoxetine)
Paliperidone
Quetiapine
Risperidone
Tefludazine
Zicronapine
Ziprasidone
Zotepine
Others: Berupipam
Ecopipam
EEDQ
Metitepine (methiothepin)
Odapipam
Perlapine
SCH-23390
D2-likeAgonists
Adamantanes: Amantadine
Memantine
Rimantadine
Aminotetralins: 5-OH-DPAT
7-OH-DPAT
8-OH-PBZI
Rotigotine
UH-232
Ergolines: Bromocriptine
Cabergoline
Chanoclavine
Dihydroergocryptine
Epicriptine
Ergocornine
Lergotrile
Lisuride
LSD
Pergolide
Terguride
Dihydrexidine derivatives: 2-OH-NPA
Ciladopa
Dihydrexidine
Dinoxyline
N,N-Propyldihydrexidine
Phenethylamines: Deoxyepinephrine (N-methyldopamine, epinine)
Dopexamine
Etilevodopa
Ibopamine
L-DOPA (levodopa)
L-Phenylalanine
L-Tyrosine
Melevodopa
XP21279
Atypical antipsychotics: Alentemol (U-66444B)
Aripiprazole (+sertraline)
Aripiprazole lauroxil
Bifeprunox
Brexpiprazole
Brilaroxazine
Cariprazine
F-15063
Lumateperone
Norclozapine
Others: 3-PPP
A-412997
ABT-670
ABT-724
Adrafinil
Aplindore
Apomorphine
Arketamine
Armodafinil
BP-897
Captodiame
CP-226,269
Dizocilpine
Esketamine
Flibanserin
Ketamine
Mesulergine
Modafinil
OSU-6162
Pardoprunox
PD-128,907
PD-168,077
PF-219,061
PF-592,379
Phencyclidine
Piribedil
Pramipexole
Preclamol
Propylnorapomorphine
Pukateine
Quinagolide
Quinelorane
Quinpirole
RDS-127
Ro10-5824
Ropinirole
Roxindole
Salvinorin A
SKF-83,959
Sumanirole
Talipexole
Umespirone
WAY-100,635
Antagonists
Typical antipsychotics: Acepromazine
Acetophenazine
Azaperone
Benperidol
Bromperidol
Butaclamol
Butaperazine
Chloracizine
Chlorproethazine
Chlorpromazine
Chlorprothixene
Ciclindole
Clopenthixol
Clothixamide
Clopimozide
Droperidol
Fluacizine
Fluanisone
Flucindole
Fluotracen
Flupentixol (flupenthixol) (+melitracen)
Fluphenazine
Fluprothixene
Fluspirilene
Haloperidol
Homopipramol
Lenperone
Levomepromazine (methotrimeprazine)
Levosulpiride
Loxapine
Mesoridazine
Moperone
Naranol
Nemonapride
Penfluridol
Perathiepin
Perazine
Pericyazine (periciazine)
Perphenazine (+amitriptyline)
Piflutixol (pifluthixol)
Pimozide
Pipamperone
Preclamol
Prochlorperazine
Promazine
Prothipendyl
Spiperone (spiroperidol)
Sulforidazine
Sulpiride
Sultopride
Teflutixol
Thiopropazate
Thioproperazine
Thioridazine
Thiothixene
Timiperone
Trifluoperazine (+tranylcypromine)
Triflupromazine
Trifluperidol
Zetidoline
Zuclopenthixol
Atypical antipsychotics: Amisulpride
Asenapine
BL-1020
Blonanserin
Carpipramine
Cinuperone
Clocapramine
Clorotepine
Clotiapine (clothiapine)
Clozapine
Cyamemazine
DHA-clozapine
Dixyrazine
Elopiprazole
Flumezapine
Fluperlapine
Gevotroline
Iloperidone
Lurasidone
Mazapertine
Melperone
Molindone
Mosapramine
Ocaperidone
Olanzapine (+fluoxetine)
Paliperidone
Perospirone
Piperacetazine
Pipotiazine
Piquindone
Quetiapine
Remoxipride
Risperidone
Sertindole
Tefludazine
Tenilapine
Tiospirone
Veralipride
Zicronapine
Ziprasidone
Zotepine
Antiemetics/gastroprokinetics/sedatives: Aceprometazine
AS-8112
Alimemazine
Alizapride
Benzquinamide
Bromopride
Clebopride
Deudomperidone
Domperidone
Eticlopride
Hydroxyzine
Itopride
Metoclopramide
Metopimazine
Promethazine
Thiethylperazine
Trimethobenzamide
Antidepressants: Amoxapine
Nefazodone
Opipramol
Propiomazine
Trimipramine
Others: 3-PPP
Alpiropride
Azapride
Bromerguride
Bromocriptine
Buspirone
Desmethoxyfallypride
EEDQ
F-15063
Fallypride
Fananserin
Fenfluramine
Iodobenzamide
Isocorypalmine
L-741,626
L-745,870
Levofenfluramine
LEK-8829
Metergoline
Metitepine (methiothepin)
N-Methylspiperone
Nafadotride
Nuciferine
PNU-99,194
Pridopidine
Raclopride
Sarizotan
SB-277,011-A
Seridopidine
Sonepiprazole
Spiroxatrine
Stepholidine
SV-293
Terguride
Tetrahydropalmatine
Tiapride
UH-232
Yohimbine

See also: Receptor/signaling modulators
Adrenergics
Serotonergics
Monoamine reuptake inhibitors
Monoamine releasing agents
Monoamine metabolism modulators
Monoamine neurotoxins

showvteIon channel modulatorsCalciumVDCCsBlockers
L-type-selective: Dihydropyridines: Amlodipine
Aranidipine
Azelnidipine
Barnidipine
Clevidipine
Cronidipine
Darodipine
Dexniguldipine
Elgodipine
Elnadipine
Felodipine
Flordipine
Furnidipine
Iganidipine
Isradipine
Lacidipine
Lemildipine
Lercanidipine
Levamlodipine
Levniguldipine
Manidipine
Mepirodipine
Mesudipine
Nicardipine
Nifedipine
Niguldipine
Niludipine
Nilvadipine
Nimodipine
Nisoldipine
Nitrendipine
Olradipine
Oxodipine
Palonidipine
Pranidipine
Ryodipine (riodipine)
Sagandipine
Sornidipine
Teludipine
Tiamdipine
Trombodipine
Vatanidipine; Diltiazem derivatives: Clentiazem
Diltiazem
Iprotiazem
Nictiazem
Siratiazem; Phenylalkylamines: Anipamil
Dagapamil
Devapamil
Dexverapamil
Emopamil
Etripamil
Falipamil
Gallopamil
Levemopamil
Nexopamil
Norverapamil
Ronipamil
Tiapamil
Verapamil; Others: AH-1058
Brinazarone
Budiodarone
Celivarone
Cyproheptadine
Dronedarone
Fantofarone
SR-33805
Tetrahydropalmatine
N-type-selective: ω-Conotoxins
ω-Conotoxin GVIA
Caroverine
Huwentoxin XVI
Leconotide (ω-conotoxin CVID)
PD-173212
Ralfinamide
Safinamide
Z160
Ziconotide (ω-conotoxin MVIIA)
P-type-selective: ω-Agatoxin IVA
ω-Agatoxin IVB
R-type-selective: SNX-482
T-type-selective: ABT-639
ML-218
Niflumic acid
NNC 55-0396
ProTx I
Z944
Zonisamide
Non-selective: ω-Agatoxin TK
ω-Conotoxin MVIIC
Benidipine
Bepridil
Cilnidipine
Cinnarizine
Dotarizine
Efonidipine
Flunarizine
Lamotrigine
Levetiracetam
Lomerizine
Loperamide
Mibefradil
NP078585
Ruthenium red
TROX-1
α2δ subunit-selective (gabapentinoids): 4-Methylpregabalin
Arbaclofen
Arbaclofen placarbil
Atagabalin
Baclofen
Gabapentin
Gabapentin enacarbil
Imagabalin
Mirogabalin
PD-200,347
PD-217,014
PD-299,685
Phenibut
Pregabalin
Others/unsorted: Bencyclane
Berbamine
Bevantolol
Canadine
Carboxyamidotriazole
Cycleanine
Dauricine
Dimeditiapramine
Diproteverine
Enpiperate
Eperisone
Elpetrigine
Ethadione
Ethanol (alcohol)
Ethosuximide
Fasudil
Fendiline
Fostedil
Imepitoin
JTV-519
Lidoflazine
Magnesium
Manoalide
Mesuximide
Monatepil
Naftopidil
Ochratoxin A
Osthol
Otilonium bromide
Paramethadione
Phensuximide
Pinaverium bromide
Prenylamine
Rhynchophylline
Sesamodil
Silperisone
Sipatrigine
Terodiline
Tetrandrine
Tolperisone
Trimethadione
Valperinol
Activators
L-type-selective: Bay K8644
PotassiumVGKCsBlockers
3,4-Diaminopyridine (amifampridine)
4-Aminopyridine (fampridine/dalfampridine)
Adekalant
Almokalant
Amiodarone
Azimilide
Bretylium
Bunaftine
Charybdotoxin
Clamikalant
Conotoxins
Dalazatide
Dendrotoxin
Dofetilide
Dronedarone
E-4031
Hanatoxin
HgeTx1
HsTx1
Ibutilide
Inakalant
Kaliotoxin
Linopirdine
Lolitrem B
Maurotoxin
Nifekalant
Notoxin
Paxilline
Pinokalant
Quinidine
ShK-186
Sotalol
Tedisamil
Terikalant
Tetraethylammonium
Vernakalant
hERG (KCNH2, Kv11.1)-specific: Ajmaline
Amiodarone
AmmTX3
Astemizole
Azaspiracid
AZD1305
Azimilide
Bedaquiline
BeKm-1
BmTx3
BRL-32872
Chlorpromazine
Cisapride
Clarithromycin
Darifenacin
Dextropropoxyphene
Diallyl trisulfide
Domperidone
E-4031
Ergtoxins
Erythromycin
Gigactonine
Haloperidol
Ketoconazole
Norpropoxyphene
Orphenadrine
Pimozide
PNU-282,987
Promethazine
Quinidine
Ranolazine
Roxithromycin
Sertindole
Solifenacin
Tamulotoxin
Terodiline
Terfenadine
Thioridazine
Tolterodine
Vanoxerine
Vernakalant
KCNQ (Kv7)-specific: Linopirdine
XE-991
Spooky toxin (SsTx)
Activators
KCNQ (Kv7)-specific: Flupirtine
Retigabine
IRKsBlockers
KATP-specific: Acetohexamide
Carbutamide
Chlorpropamide
Glibenclamide (glyburide)
Glibornuride
Glicaramide
Gliclazide
Glimepiride
Glipizide
Gliquidone
Glisoxepide
Glyclopyramide
Glycyclamide
Metahexamide
Mitiglinide
Nateglinide
Repaglinide
Tolazamide
Tolbutamide
GIRK-specific: Barium
Caramiphen
Cloperastine
Clozapine
Dextromethorphan
Ethosuximide
Ifenprodil
Tertiapin
Tipepidine
Activators
KATP-specific: Aprikalim
Bimakalim
Cromakalim
Diazoxide
Emakalim
Levcromakalim
Mazokalim
Minoxidil
Naminidil
Nicorandil
Pinacidil
Rilmakalim
Sarakalim
GIRK-specific: ML-297 (VU0456810)
KCaBlockers
BKCa-specific: Ethanol (alcohol)
GAL-021
Activators
BKCa-specific: Flufenamic acid
Meclofenamic acid
Niflumic acid
Nimesulide
Rottlerin (mallotoxin)
Tolfenamic acid
K2PsBlockers
12-O-Tetradecanoylphorbol-13-acetate
Arachidonic acid
Fluoxetine
Norfluoxetine
Activators
Riluzole
SodiumVGSCsBlockers
Antianginals: Ranolazine
Antiarrhythmics (class I): Ajmaline
Aprindine
Disopyramide
Dronedarone
Encainide
Flecainide
Lidocaine
Lorajmine
Lorcainide
Mexiletine
Moricizine
Pilsicainide
Prajmaline
Procainamide
Propafenone
Quinidine
Sparteine
Tocainide
Anticonvulsants: Acetylpheneturide
Carbamazepine
Cenobamate
Chlorphenacemide
Elpetrigine
Eslicarbazepine acetate
Ethotoin
Fosphenytoin
Lacosamide
Licarbazepine
Mephenytoin
Oxcarbazepine
Oxitriptyline
Phenacemide
Pheneturide
Phenytoin
Rufinamide
Sipatrigine
Topiramate
Sodium valproate
Valnoctamide
Valproate pivoxil
Valproate semisodium
Valproic acid
Valpromide
Zonisamide
Local anesthetics: pFBT
Amylocaine
Articaine
Benzocaine
Bupivacaine (Levobupivacaine, Ropivacaine)
Butacaine
Butamben
Chloroprocaine
Cinchocaine
Cocaine
Cyclomethycaine
Dimethocaine
Diphenhydramine
Etidocaine
Hexylcaine
Iontocaine
Lidocaine
Mepivacaine
Meprylcaine
Metabutoxycaine
Orthocaine
Piperocaine
Prilocaine
Procaine
Propoxycaine
Proxymetacaine
Risocaine
Tetracaine
Trimecaine
Analgesics: AZD-3161
DSP-2230
Funapide
GDC-0276
NKTR-171
PF-04531083
PF-05089771
Ralfinamide
Raxatrigine
RG7893 (GDC-0287)
Toxins: Conotoxins
Neosaxitoxin
Saxitoxin
Tetrodotoxin
Zetekitoxin AB
Others: Buprenorphine
Evenamide
Menthol (mint)
Safinamide
Tricyclic antidepressants
Activators
Aconitine
Atracotoxins (ω-Atracotoxin, Robustoxin, Versutoxin)
Batrachotoxin
Ciguatoxins
Grayanotoxins
Poneratoxin
ENaCBlockers
Amiloride
Benzamil
Triamterene
Activators
Solnatide
ASICsBlockers
A-317567
Amiloride
Aspirin
Ibuprofen
PcTX1
ChlorideCaCCsBlockers
Crofelemer
DIDS
Ethacrynic acid
Flufenamic acid
Fluoxetine
Furosemide
Glibenclamide
Mefloquine
Mibefradil
Niflumic acid
Activators
Carbachol
CFTRBlockers
Glibenclamide
Lonidamine
Piretanide
Activators
1,7-Phenanthroline
1,10-Phenanthroline
4,7-Phenanthroline
7,8-Benzoquinoline
Ivacaftor
Phenanthridine
UnsortedBlockers
Bumetanide
Flufenamic acid
Meclofenamic acid
Mefenamic acid
Mepacrine
Niflumic acid
Talniflumate
Tolfenamic acid
Trifluoperazine
OthersTRPs
See here instead.
LGICs
See here instead.
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
showvteIonotropic glutamate receptor modulatorsAMPAR
Agonists: Main site agonists: 5-Fluorowillardiine
Acromelic acid (acromelate)
AMPA
BOAA
Domoic acid
Glutamate
Ibotenic acid
Proline
Quisqualic acid
Willardiine; Positive allosteric modulators: Aniracetam
BIIB-104 (PF-04958242)
Cyclothiazide
CX-516
CX-546
CX-614
Farampator (CX-691, ORG-24448)
CX-717
CX-1739
CX-1942
Diazoxide
Hydrochlorothiazide (HCTZ)
IDRA-21
LY-392098
LY-395153
LY-404187
LY-451646
LY-503430
Mibampator (LY-451395)
Nooglutyl
ORG-26576
Oxiracetam
PEPA
Piracetam
Pramiracetam
S-18986
Tulrampator (S-47445, CX-1632)
Antagonists: ACEA-1011
ATPO
Becampanel
Caroverine
CNQX
Dasolampanel
DNQX
Fanapanel (MPQX)
GAMS
Kaitocephalin
Kynurenic acid
Kynurenine
Licostinel (ACEA-1021)
NBQX
PNQX
Selurampanel
Tezampanel
Theanine
Topiramate
YM90K
Zonampanel; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
Cyclopropane
Enflurane
Ethanol (alcohol)
Evans blue
GYKI-52466
GYKI-53655
Halothane
Irampanel
Isoflurane
Perampanel
Pregnenolone sulfate
Sevoflurane
Talampanel; Unknown/unsorted antagonists: Minocycline
KAR
Agonists: Main site agonists: 5-Bromowillardiine
5-Iodowillardiine
Acromelic acid (acromelate)
AMPA
ATPA
Domoic acid
Glutamate
Ibotenic acid
Kainic acid
LY-339434
Proline
Quisqualic acid
SYM-2081; Positive allosteric modulators: Cyclothiazide
Diazoxide
Enflurane
Halothane
Isoflurane
Antagonists: ACEA-1011
CNQX
Dasolampanel
DNQX
GAMS
Kaitocephalin
Kynurenic acid
Licostinel (ACEA-1021)
LY-382884
NBQX
NS102
Selurampanel
Tezampanel
Theanine
Topiramate
UBP-302; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
Enflurane
Ethanol (alcohol)
Evans blue
NS-3763
Pregnenolone sulfate
NMDAR
Agonists: Main site agonists: AMAA
Aspartate
Glutamate
Homocysteic acid (L-HCA)
Homoquinolinic acid
Ibotenic acid
NMDA
Proline
Quinolinic acid
Tetrazolylglycine
Theanine; Glycine site agonists: β-Fluoro-D-alanine
ACBD
ACC (ACPC)
ACPD
AK-51
Apimostinel (NRX-1074)
B6B21
CCG
D-Alanine
D-Cycloserine
D-Serine
DHPG
Dimethylglycine
Glycine
HA-966
L-687414
L-Alanine
L-Serine
Milacemide
Neboglamine (nebostinel)
Rapastinel (GLYX-13)
Sarcosine; Polyamine site agonists: Neomycin
Spermidine
Spermine; Other positive allosteric modulators: 24S-Hydroxycholesterol
DHEA (prasterone)
DHEA sulfate (prasterone sulfate)
Epipregnanolone sulfate
Plazinemdor
Pregnenolone sulfate
SAGE-201
SAGE-301
SAGE-718
Antagonists: Competitive antagonists: AP5 (APV)
AP7
CGP-37849
CGP-39551
CGP-39653
CGP-40116
CGS-19755
CPP
Kaitocephalin
LY-233053
LY-235959
LY-274614
MDL-100453
Midafotel (d-CPPene)
NPC-12626
NPC-17742
PBPD
PEAQX
Perzinfotel
PPDA
SDZ-220581
Selfotel; Glycine site antagonists: 4-Cl-KYN (AV-101)
5,7-DCKA
7-CKA
ACC
ACEA-1011
ACEA-1328
Apimostinel (NRX-1074)
AV-101
Carisoprodol
CGP-39653
CNQX
D-Cycloserine
DNQX
Felbamate
Gavestinel
GV-196771
Harkoseride
Kynurenic acid
Kynurenine
L-689560
L-701324
Licostinel (ACEA-1021)
LU-73068
MDL-105519
Meprobamate
MRZ 2/576
PNQX
Rapastinel (GLYX-13)
ZD-9379; Polyamine site antagonists: Arcaine
Co 101676
Diaminopropane
Diethylenetriamine
Huperzine A
Putrescine; Uncompetitive pore blockers (mostly dizocilpine site): 2-MDP
3-HO-PCP
3-MeO-PCE
3-MeO-PCMo
3-MeO-PCP
4-MeO-PCP
8A-PDHQ
18-MC
α-Endopsychosin
Alaproclate
Alazocine (SKF-10047)
Amantadine
Aptiganel
Argiotoxin-636
Arketamine
ARL-12495
ARL-15896-AR
ARL-16247
Budipine
Coronaridine
Delucemine (NPS-1506)
Dexoxadrol
Dextrallorphan
Dextromethadone
Dextromethorphan
Dextrorphan
Dieticyclidine
Diphenidine
Dizocilpine
Ephenidine
Esketamine
Etoxadrol
Eticyclidine
Fluorolintane
Gacyclidine
Ibogaine
Ibogamine
Indantadol
Ketamine
Ketobemidone
Lanicemine
Levomethadone
Levomethorphan
Levomilnacipran
Levorphanol
Loperamide
Memantine
Methadone
Methorphan
Methoxetamine
Methoxphenidine
Milnacipran
Morphanol
NEFA
Neramexane
Nitromemantine
Noribogaine
Norketamine
Orphenadrine
PCPr
PD-137889
Pethidine (meperidine)
Phencyclamine
Phencyclidine
Propoxyphene
Remacemide
Rhynchophylline
Rimantadine
Rolicyclidine
Sabeluzole
Tabernanthine
Tenocyclidine
Tiletamine
Tramadol; Ifenprodil (NR2B) site antagonists:
Besonprodil
Buphenine (nylidrin)
CO-101244 (PD-174494)
Eliprodil
Haloperidol
Isoxsuprine
Radiprodil (RGH-896)
Rislenemdaz (CERC-301, MK-0657)
Ro 8-4304
Ro 25-6981
Safaprodil
Traxoprodil (CP-101606); NR2A-selective antagonists: MPX-004
MPX-007
TCN-201
TCN-213; Cations: Hydrogen
Magnesium
Zinc; Alcohols/volatile anesthetics/related: Benzene
Butane
Chloroform
Cyclopropane
Desflurane
Diethyl ether
Enflurane
Ethanol (alcohol)
Halothane
Hexanol
Isoflurane
Methoxyflurane
Nitrous oxide
Octanol
Sevoflurane
Toluene
Trichloroethane
Trichloroethanol
Trichloroethylene
Urethane
Xenon
Xylene; Unknown/unsorted antagonists: ARR-15896
Bumetanide
Caroverine
Conantokin
D-αAA
Dexanabinol
Flufenamic acid
Flupirtine
FPL-12495
FR-115427
Furosemide
Hodgkinsine
Ipenoxazone (MLV-6976)
MDL-27266
Metaphit
Minocycline
MPEP
Niflumic acid
Pentamidine
Pentamidine isethionate
Piretanide
Psychotridine
Transcrocetin (saffron)
Unsorted: Allosteric modulators: AGN-241751

See also: Receptor/signaling modulators
Metabotropic glutamate receptor modulators
Glutamate metabolism/transport modulators

showvteMonoamine reuptake inhibitorsDAT(DRIs)
Piperazines: DBL-583
GBR-12783
GBR-12935
GBR-13069
GBR-13098
Nefazodone
Vanoxerine

Piperidines: 4-Fluoropethidine
Benocyclidine (BTCP)
Desoxypipradrol
Dexmethylphenidate
Difemetorex
Ethylphenidate
HDMP-28
Methylphenidate
Pethidine (meperidine)
Phencyclidine
Pipradrol
Serdexmethylphenidate
Tenocyclidine

Pyrrolidines: Diphenylprolinol
MDPV
Naphyrone
Prolintane
Pyrovalerone

Tropanes: Altropane
Benzatropine (benztropine)
Brasofensine
CFT
Cocaine
Dichloropane
Difluoropine
Etybenzatropine (ethybenztropine)
FE-β-CPPIT
FP-β-CPPIT
Ioflupane (123I)
RTI-55
RTI-112
RTI-113
RTI-121
RTI-126
RTI-150
RTI-177
RTI-229
RTI-336
Tesofensine
Troparil
Tropoxane
WF-11
WF-23
WF-31
WF-33

Others: Adrafinil
Amifitadine
Armodafinil
Amfonelic acid
Amineptine
Ansofaxine
BTQ
BTS 74,398
Bupropion
Chaenomeles speciosa
Ciclazindol
Dasotraline
Desmethylsertraline
Desmethylsibutramine (BTS-54354)
Diclofensine
Didesmethylsibutramine (BTS-54505)
Dimethocaine
Diphenylpyraline
Dizocilpine (MK-801)
DOV-102,677
DOV-216,303
Efavirenz
Ephenidine
Esketamine
EXP-561
Fencamfamin
Fezolamine
Fluorenol
GYKI-52895
Indatraline
Ketamine
Lefetamine
Levophacetoperane
Liafensine
LR-5182
Manifaxine
Mazindol
Medifoxamine
Mesocarb
Metaphit
MIN-117 (WF-516)
Modafinil
Nefopam
Nomifensine
NS-2359
O-2172
Oroxylin A
Perafensine
Pridefine
Radafaxine
Rimcazole
Sertraline
Sibutramine
Solriamfetol
Tametraline
Tedatioxetine
Tripelennamine
Venlafaxine
NET(NRIs)
Selective norepinephrine reuptake inhibitors: Amedalin
Alseroxylon
Ciclazindol
Daledalin
Edivoxetine
Esreboxetine
Lortalamine
Mazindol
Nisoxetine
Reboxetine
Talopram
Talsupram
Tandamine
Teniloxazine
Viloxazine

Norepinephrine–dopamine reuptake inhibitors: Amineptine
Bupropion
Fencamine
Fencamfamin
Hydroxybupropion
Lefetamine
Levophacetoperane
LR-5182
Manifaxine
Methylphenidate
Nomifensine
O-2172
Radafaxine
Serdexmethylphenidate
Solriamfetol

Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine)
CP-39,332
Desvenlafaxine
Duloxetine
Eclanamine
Levomilnacipran
McN5652
Milnacipran
N-Methyl-PPPA
Nafenodone
PPPA
Tofenacin
Venlafaxine

Serotonin–norepinephrine–dopamine reuptake inhibitors: 3,3-Diphenylcyclobutanamine
Amifitadine
Ansofaxine
Bicifadine
Brasofensine
Centanafadine
Cocaine
Dasotraline
Desmethylsertraline
Desmethylsibutramine (BTS-54354)
Diclofensine
Didesmethylsibutramine (BTS-54505)
DOV-102677
DOV-216303
EXP-561
Fezolamine
HDMP-28
Indatraline
JNJ-7925476
JZ-IV-10
Liafensine
Mazindol
Naphyrone
Nefazodone
Nefopam
NS-2359
Perafensine
PRC200
Pridefine
SEP-228431
SEP-228432
Sibutramine
Tedatioxetine
Tesofensine
Tropanes (e.g., cocaine)

Tricyclic antidepressants: Amitriptyline
Butriptyline
Cianopramine
Clomipramine
Desipramine
Dosulepin (dothiepin)
Doxepin
Imipramine
Lofepramine
Melitracen
Nortriptyline
Protriptyline
Trimipramine

Tetracyclic antidepressants: Amoxapine
Maprotiline
Mianserin
Oxaprotiline
Setiptiline

Others: Antihistamines (e.g., brompheniramine, chlorphenamine, pheniramine, tripelennamine)
Antipsychotics (e.g., loxapine, ziprasidone)
Arylcyclohexylamines (e.g., ketamine, phencyclidine)
Dopexamine
Ephenidine
Ginkgo biloba
Indeloxazine
Nefazodone
Opioids (e.g., desmetramadol, methadone, pethidine (meperidine), tapentadol, tramadol, levorphanol)
SERT(SRIs)
Selective serotonin reuptake inhibitors: 6-Nitroquipazine
Alaproclate
Centpropazine
Cericlamine
Citalopram
Dapoxetine
Desmethylcitalopram
Didesmethylcitalopram
Escitalopram
Femoxetine
Fluoxetine
Fluvoxamine
Indalpine
Ifoxetine
Norfluoxetine
Omiloxetine
Panuramine
Paroxetine
PIM-35
Pirandamine
RTI-353
Seproxetine
Sertraline
Zimelidine
Selective serotonin reuptake inhibitors and serotonin receptor modulators: Etoperidone
Litoxetine
Lubazodone
LY-393558
Quipazine
SB-649915
TGBA01AD
Trazodone
Vilazodone
Vortioxetine

Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine)
Bicifadine
CP-39332
Desvenlafaxine
Duloxetine
Eclanamine
Levomilnacipran
McN5652
Milnacipran
N-Methyl-PPPA
PPPA
Tofenacin
Venlafaxine

Serotonin–norepinephrine–dopamine reuptake inhibitors: 3,3-Diphenylcyclobutanamine
Amifitadine
Ansofaxine
Bicifadine
Brasofensine
Centanafadine
Cocaine
Dasotraline
Desmethylsertraline
Desmethylsibutramine (BTS-54354)
Diclofensine
Didesmethylsibutramine (BTS-54505)
DOV-102677
DOV-216303
EXP-561
Fezolamine
HDMP-28
Indatraline
JNJ-7925476
JZ-IV-10
Liafensine
Mazindol
Naphyrone
Nefazodone
Nefopam
NS-2359
Perafensine
PRC200
Pridefine
SEP-228431
SEP-228432
Sibutramine
Tedatioxetine
Tesofensine
Tropanes (e.g., cocaine)

Tricyclic antidepressants: Amitriptyline
Cianopramine
Clomipramine
Cyanodothiepin
Desipramine
Dosulepin (dothiepin)
Doxepin
Imipramine
Lofepramine
Nortriptyline
Pipofezine
Protriptyline

Others: A-80426
Amoxapine
Antihistamines (e.g., brompheniramine, chlorphenamine, dimenhydrinate, diphenhydramine, mepyramine (pyrilamine), pheniramine, tripelennamine)
Antipsychotics (e.g., loxapine, ziprasidone)
Arylcyclohexylamines (e.g., 3-MeO-PCP, esketamine, ketamine, methoxetamine, phencyclidine)
Cyclobenzaprine
Delucemine
Dextromethorphan
Dextrorphan
Efavirenz
Hypidone
Medifoxamine
Mesembrine
Mifepristone
MIN-117 (WF-516)
N-Me-5-HT
Opioids (e.g., dextropropoxyphene, methadone, pethidine (meperidine), levorphanol, tapentadol, tramadol)
Roxindole
VMATs
Amiodarone
Amphetamines (e.g., amphetamine, methamphetamine, MDMA)
APP
AZIK
Bietaserpine
Deserpidine
Deutetrabenazine
Dihydrotetrabenazine
Efavirenz
GBR-12935
GZ-793A
Ibogaine
Ketanserin
Lobeline
Methoxytetrabenazine
Reserpine
Rose bengal
Tetrabenazine
Valbenazine
Vanoxerine (GBR-12909)
Others
DAT enhancers: Luteolin
DAT modulators: Agonist-like: SoRI-9804
SoRI-20040; Antagonist-like: SoRI-20041
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
showvteOpioid receptor modulatorsMOR
Agonists (abridged; see here for a full list): 3-HO-PCP
7-Acetoxymitragynine
7-Hydroxymitragynine
ψ-Akuammigine
α-Chlornaltrexamine
α-Narcotine
Acetyldihydrocodeine
Acetylfentanyl
Acrylfentanyl
Adrenorphin (metorphamide)
AH-7921
Akuammicine
Akuammidine
Alfentanil
Anileridine
Apparicine
β-Endorphin
BAM-12P
BAM-18P
BAM-22P
Benzhydrocodone
Benzylmorphine
Bezitramide
Biphalin
BU08070
Buprenorphine
Butorphan
Butorphanol
Butyrfentanyl
BW373U86
Carfentanil
Casokefamide
Cebranopadol
Chloroxymorphamine
Codeine
DADLE
DAMGO (DAGO)
Dermorphin
Desmetramadol (desmethyltramadol)
Desomorphine
Dextromoramide
Dextropropoxyphene (propoxyphene)
Dezocine
Dimenoxadol
Dimethylaminopivalophenone
Eluxadoline
Diamorphine (heroin)
Dihydrocodeine
Dihydroetorphine
Dihydromorphine
Dinalbuphine sebacate
Diphenoxylate
Dipipanone
Dynorphin A
Embutramide
Endomorphin-1
Endomorphin-2
Eseroline
Ethylmorphine
Etorphine
Fentanyl
Fluorophen
Frakefamide
Furanylfentanyl
Hemorphin-4
Herkinorin
Hodgkinsine
Hydrocodone
Hydromorphinol
Hydromorphone
IBNtxA
Ketamine
Ketobemidone
Kratom
Laudanosine
Lefetamine
Leu-enkephalin
Levacetylmethadol
Levomethorphan
Levorphanol
Lexanopadol
Loperamide
Loxicodegol
LS-115509
Matrine
Meptazinol
Met-enkephalin (metenkefalin)
Methadone
Metkefamide
Metopon
Mitragynine
Mitragynine pseudoindoxyl
Morphiceptin
Morphine
Nalbuphine
NalBzOH
Nalmexone
Naltalimide
Neopine
NFEPP
Nicocodeine
Nicodicodine
Nicomorphine
NKTR-181
Norketamine
Nufenoxole
Octreotide
Oliceridine
OM-3-MNZ
Oripavine
Oxycodone
Oxymorphazone
Oxymorphonazine
Oxymorphone
Oxymorphone phenylhydrazone
OxyPNPH
Papaver somniferum (opium)
Pentazocine
Pericine
Pethidine (meperidine)
Phenazocine
Phencyclidine
Piminodine
Piritramide
PL-017
Prodine
Propiram
PZM21
Racemethorphan
Racemorphan
Remifentanil
Salsolinol
SC-17599
Sinomenine
Sufentanil
Tapentadol
Tetrahydropapaveroline
TH-030418
Thebaine
Thienorphine
Tianeptine
Tilidine
Tramadol
Trimebutine
TRIMU 5
TRV734
Tubotaiwine
U-47700
Valorphin
Viminol
Xorphanol
PAMs: BMS-986121
BMS-986122
Antagonists: (3S,4S)-Picenadol
2-(S)-N,N-(R)-Viminol
3CS-nalmefene
4-Caffeoyl-1,5-quinide
4′-Hydroxyflavanone
4',7-Dihydroxyflavone
6β-Naltrexol
6β-Naltrexol-d4
18-MC
α-Gliadin
β-Chlornaltrexamine
β-Funaltrexamine
Akuammine
Alvimopan
AM-251
Apigenin
AT-076
Axelopran
Bevenopran
Catechin
Catechin gallate
Clocinnamox
CTAP
CTOP
Cyclofoxy
Cyprodime
Diacetylnalorphine
Diprenorphine
ECG
EGC
Epicatechin
Eptazocine
Gemazocine
Ginsenoside R
Hyperoside
Ibogaine
JDTic
Levallorphan
Lobeline
LY-255582
LY-2196044
Methocinnamox
Methylnaltrexone
Methylsamidorphan chloride
Naldemedine
Nalmefene
Nalodeine (N-allylnorcodeine)
Nalorphine
Nalorphine dinicotinate
Naloxazone
Naloxegol
Naloxol
Naloxonazine
Naloxone
Naltrexazone
Naltrexonazine
Naltrexone
Naltrindole
Naringenin
Noribogaine
Oxilorphan
Pawhuskin A
Rimonabant
Quadazocine
Samidorphan
Taxifolin
Unknown/unsorted: Cannabidiol
Coronaridine
Cyproterone acetate
Dihydroakuuamine
Tabernanthine
Tetrahydrocannabinol
DOR
Agonists: 3CS-nalmefene
6'-GNTI
7-SIOM
ADL-5747 (PF-04856881)
ADL-5859
Alazocine (SKF-10047)
Amoxapine
AR-M100390 (ARM390)
AZD2327
β-Endorphin
BAM-18P
Biphalin
BU-48
Butorphan
Butorphanol
BW373U86
Casokefamide
Cebranopadol
Codeine
Cyclazocine
DADLE
Deltorphin A
Deltorphin I
Deltorphin II
Desmethylclozapine
Desmetramadol (desmethyltramadol)
Dezocine
Diamorphine (heroin)
Dihydroetorphine
Dihydromorphine
DPDPE
DPI-221
DPI-3290
DSLET
Ethylketazocine
Etorphine
Fentanyl
FIT
Fluorophen
Hemorphin-4
Hydrocodone
Hydromorphone
Ibogaine
Isomethadone
JNJ-20788560
KNT-127
Kratom
Laudanosine
Leu-enkephalin
Levomethorphan
Levorphanol
Lexanopadol
Lofentanil
Met-enkephalin (metenkefalin)
Metazocine
Metkefamide
Mitragynine
Mitragynine pseudoindoxyl
Morphine
N-Phenethyl-14-ethoxymetopon
Norbuprenorphine
NalBzOH
Oripavine
Oxycodone
Oxymorphone
Pethidine (meperidine)
Proglumide
Racemethorphan
Racemorphan
RWJ-394674
Samidorphan
SB-235863
SNC-80
SNC-162
TAN-67 (SB-205,607)
TH-030418
Thebaine
Thiobromadol (C-8813)
Tonazocine
Tramadol
TRV250
Xorphanol
Zenazocine
Antagonists: 4',7-Dihydroxyflavone
5'-NTII
6β-Naltrexol
6β-Naltrexol-d4
α-Santolol
β-Chlornaltrexamine
Apigenin
AT-076
Axelopran
Bevenopran
BNTX
Catechin
Catechin gallate
Clocinnamox
Diacetylnalorphine
Diprenorphine
ECG
EGC
Eluxadoline
Epicatechin
ICI-154129
ICI-174864
LY-255582
LY-2196044
Methylnaltrexone
Methylnaltrindole
N-Benzylnaltrindole
Nalmefene
Nalorphine
Naltrexone
Naltriben
Naltrindole
Naloxone
Naringenin
Noribogaine
Pawhuskin A
Quadazocine
SDM25N
SoRI-9409
Taxifolin
Thienorphine
Unknown/unsorted: 18-MC
Cannabidiol
Coronaridine
Cyproterone acetate
Tabernanthine
Tetrahydrocannabinol
KOR
Agonists: 3CS-nalmefene
6'-GNTI
8-CAC
18-MC
14-Methoxymetopon
β-Chlornaltrexamine
β-Funaltrexamine
Adrenorphin (metorphamide)
Akuuamicine
Alazocine (SKF-10047)
Allomatrine
Apadoline
Asimadoline
BAM-12P
BAM-18P
BAM-22P
Big dynorphin
Bremazocine
BRL-52537
Butorphan
Butorphanol
BW373U86
Cebranopadol
Ciprefadol
CR665
Cyclazocine
Cyclorphan
Cyprenorphine
Desmetramadol (desmethyltramadol)
Diamorphine (heroin)
Diacetylnalorphine
Difelikefalin
Dihydroetorphine
Dihydromorphine
Dinalbuphine sebacate
Diprenorphine
Dynorphin A
Dynorphin B (rimorphin)
Eluxadoline
Enadoline
Eptazocine
Erinacine E
Ethylketazocine
Etorphine
Fedotozine
Fentanyl
Gemazocine
GR-89696
GR-103545
Hemorphin-4
Herkinorin
HS665
Hydromorphone
HZ-2
Ibogaine
ICI-199,441
ICI-204,448
Ketamine
Ketazocine
Laudanosine
Leumorphin (dynorphin B-29)
Levallorphan
Levomethorphan
Levorphanol
Lexanopadol
Lofentanil
LPK-26
Lufuradom
Matrine
MB-1C-OH
Menthol
Metazocine
Metkefamide
Mianserin
Mirtazapine
Morphine
Moxazocine
MR-2034
N-MPPP
Nalbuphine
NalBzOH
Nalfurafine
Nalmefene
Nalodeine (N-allylnorcodeine)
Nalorphine
Naltriben
Niravoline
Norbuprenorphine
Norbuprenorphine-3-glucuronide
Noribogaine
Norketamine
Oripavine
Oxilorphan
Oxycodone
Pentazocine
Pethidine (meperidine)
Phenazocine
Proxorphan
Racemethorphan
Racemorphan
RB-64
Salvinorin A (salvia)
Salvinorin B ethoxymethyl ether
Salvinorin B methoxymethyl ether
Samidorphan
Spiradoline (U-62,066)
TH-030418
Thienorphine
Tifluadom
Tricyclic antidepressants (e.g., amitriptyline, desipramine, imipramine, nortriptyline)
U-50488
U-54,494A
U-69,593
Xorphanol
Antagonists: 4′-Hydroxyflavanone
4',7-Dihydroxyflavone
5'-GNTI
6'-GNTI
6β-Naltrexol
6β-Naltrexol-d4
β-Chlornaltrexamine
Buprenorphine/samidorphan
Amentoflavone
ANTI
Apigenin
Arodyne
AT-076
Aticaprant
Axelopran
AZ-MTAB
Binaltorphimine
BU09059
Buprenorphine
Catechin
Catechin gallate
CERC-501 (LY-2456302)
Clocinnamox
Cyclofoxy
Dezocine
DIPPA
EGC
ECG
Epicatechin
Hyperoside
JDTic
LY-255582
LY-2196044
LY-2444296
LY-2459989
LY-2795050
MeJDTic
Methylnaltrexone
ML190
ML350
MR-2266
N-Fluoropropyl-JDTic
Naloxone
Naltrexone
Naltrindole
Naringenin
Norbinaltorphimine
Noribogaine
Pawhuskin A
PF-4455242
RB-64
Quadazocine
Taxifolin
UPHIT
Zyklophin
Unknown/unsorted: Akuammicine
Akuammine
Coronaridine
Cyproterone acetate
Dihydroakuuamine
Ibogamine
Tabernanthine
NOP
Agonists: (Arg14,Lys15)Nociceptin
((pF)Phe4)Nociceptin(1-13)NH2
(Phe1Ψ(CH2-NH)Gly2)Nociceptin(1-13)NH2
Ac-RYYRWK-NH2
Ac-RYYRIK-NH2
BU08070
Buprenorphine
Cebranopadol
Dihydroetorphine
Etorphine
JNJ-19385899
Levomethorphan
Levorphanol
Lexanopadol
MCOPPB
MT-7716
NNC 63-0532
Nociceptin (orphanin FQ)
Nociceptin (1-11)
Nociceptin (1-13)NH2
Norbuprenorphine
Racemethorphan
Racemorphan
Ro64-6198
Ro65-6570
SCH-221510
SCH-486757
SR-8993
SR-16435
Sunobinop (S-117957)
TH-030418
Antagonists: (Nphe1)Nociceptin(1-13)NH2
AT-076
BAN-ORL-24
BTRX-246040 (LY-2940094)
J-113,397
JTC-801
NalBzOH
Nociceptin (1-7)
Nocistatin
SB-612,111
SR-16430
Thienorphine
Trap-101
UFP-101
Unsorted
β-Casomorphins
Amidorphin
BAM-20P
Cytochrophin-4
Deprolorphin
Gliadorphin (gluteomorphin)
Gluten exorphins
Hemorphins
Kava constituents
MEAGL
MEAP
NEM
Neoendorphins
Nepetalactone (catnip)
Peptide B
Peptide E
Peptide F
Peptide I
Rubiscolins
Soymorphins
Others
Enkephalinase inhibitors: Amastatin
BL-2401
Candoxatril
D -Phenylalanine
Dexecadotril (retorphan)
Ecadotril (sinorphan)
Kelatorphan
Racecadotril (acetorphan)
RB-101
RB-120
RB-3007
Opiorphan
Selank
Semax
Spinorphin
Thiorphan
Tynorphin
Ubenimex (bestatin)
Propeptides: β-Lipotropin (proendorphin)
Prodynorphin
Proenkephalin
Pronociceptin
Proopiomelanocortin (POMC)
Others: Kyotorphin (met-enkephalin releaser/degradation stabilizer)

showvteSigma receptor modulatorsσ1
Agonists: 3-PPP
4-PPBP
5-MeO-DMT
Alazocine (SKF-10047)
Amantadine
Arketamine
BD-737
BD-1052
Blarcamesine
Captodiame
Citalopram
CGRP
Cloperastine
Cocaine
Cutamesine (SA-4503)
Cyclazocine
Dehydroepiandrosterone (DHEA) (prasterone)
Dehydroepiandrosterone sulfate (DHEA-S) (prasterone sulfate)
Dextrallorphan
Dextromethorphan (DXM)
Dextrorphan (DXO)
Dimemorfan
Dimethyltryptamine (DMT)
Ditolylguanidine (DTG)
Donepezil
Eliprodil
Escitalopram
Fabomotizole (afobazole)
Fluoxetine
Fluvoxamine
Ifenprodil
Igmesine (JO-1784)
IPAB
Ketamine
L-687384
MDMA (midomafetamine)
Memantine
Methamphetamine
Methoxetamine
Methylphenidate
Nepinalone
Neuropeptide Y
Noscapine
OPC-14523
Opipramol
Pentazocine
Pentoxyverine (carbetapentane)
PRE-084
Pregnenolone
Pregnenolone sulfate
Pridopidine
Racemethorphan (methorphan)
Racemorphan (morphanol)
UMB-23
UMB-82
Antagonists: 3-PPP
AC-927
BD-1008
BD-1031
BD-1047
BD-1060
BD-1063
BD-1067
BMY-14802 (BMS-181100)
CM-156
Dup-734
E-5842
E-52862 (S1RA)
Haloperidol
LR-132
LR-172
MS-377
NE-100
NPC-16377
Panamesine (EMD-57455)
PD-144418
Pentazocine
Progesterone
Rimcazole (BW-234U)
Sertraline
SR-31742A
Allosteric modulators: Phenytoin; Positive: Methylphenylpiracetam
SOMCL-668
Unknown/unsorted: 3-Methoxydextrallorphan
3-MeO-PCP
4C-T-2
4-IBP
4-IPBS
4-MeO-PCP
5-MeO-DALT
5-MeO-DiPT
Amitriptyline
Azidopamil
Chlorpromazine
Clemastine
Clomipramine
Clorgiline
D-Deprenyl
DiPT
DPT
Ibogaine
Imipramine
KCR-12-83.1
Nemonapride
Noribogaine
RHL-033
RS-67,333
RTI-55
Saffron
Safinamide
Selegiline
Spipethiane
Trifluoperazine
W-18
YKP10A
σ2
Agonists: 3-PPP
Arketamine
BD-1047
BD1063
Ditolylguanidine (DTG)
DKR-1005
DKR-1051
Haloperidol
Ifenprodil
Ketamine
MDMA (midomafetamine)
Methamphetamine
OPC-14523
Opipramol
PB-28
Phencyclidine
Siramesine (Lu 28-179)
UKH-1114
Antagonists: AC-927
BD-1008
BD-1067
CM-156
CT-1812
LR-172
MIN-101
Panamesine (EMD-57455)
SAS-0132
Unknown/unsorted: 3-Methoxydextrallorphan
3-MeO-PCE
4-MeO-PCP
5-MeO-DALT
5-MeO-DiPT
Clemastine
DiPT
DPT
Ibogaine
Nemonapride
Nepinalone
Noribogaine
Pentazocine
RS-67,333
Safinamide
TMA
UMB-23
UMB-82
W-18
Unsorted
Agonists: Berberine
Ethylketazocine
Fourphit
Metaphit
Naluzotan
Tapentadol
Tenocyclidine
Antagonists: AHD1
AZ66
Lamotrigine
Naloxone
SM-21
UMB-100
UMB-101
UMB-103
UMB-116
YZ-011
YZ-069
YZ-185
Allosteric modulators: SKF-83959
Unknown/unsorted: 18-Methoxycoronaridine
BMY-13980
Butaclamol
Caramiphen
Carvotroline
Chlorphenamine (chlorpheniramine)
Chlorpromazine
Cinnarizine
Cinuperone
Clocapramine
Dezocine
EMD-59983
Hypericin (St. John's wort)
Fluphenazine
Gevotroline (WY-47384)
Mepyramine (pyrilamine)
Molindone
Perphenazine
Pimozide
Proadifen
Promethazine
Propranolol
Quinidine
Remoxipride
SL 82.0715
SR-31747A
Tiospirone (BMY-13859)
Venlafaxine
See also: Receptor/signaling modulators
.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine
showAuthority control General
Integrated Authority File (Germany)
National libraries
France (data)
United States






